

*Hypothesis*

Melatonin and Hippo Pathway: Is There Existing Cross-Talk?

Federica Lo Sardo ¹, Paola Muti ², Giovanni Blandino ¹ and Sabrina Strano ^{1,*}

¹ Oncogenomic and Epigenetic Unit, Molecular Chemoprevention Group, Department of Research, Diagnosis and Innovative Technologies, Translational Research Area, Regina Elena National Cancer Institute, via Elio Chianesi 53, 00144 Rome, Italy; federica.losardo@ifo.gov.it (F.L.S.); giovanni.blandino@ifo.gov.it (G.B.)

² Department of Oncology, Juravinski Cancer Center, McMaster University, Hamilton, ON L8S 4L8, Canada; muti@mcmaster.ca

* Correspondence: sabrina.strano@ifo.gov.it; Tel.: +39-06-5266-2974

Received: 3 August 2017; Accepted: 1 September 2017; Published: 6 September 2017

Abstract: Melatonin is an indolic hormone that regulates a plethora of functions ranging from the regulation of circadian rhythms and antioxidant properties to the induction and maintenance of tumor suppressor pathways. It binds to specific receptors as well as to some cytosolic proteins, leading to several cellular signaling cascades. Recently, the involvement of melatonin in cancer insurgence and progression has clearly been demonstrated. In this review, we will first describe the structure and functions of melatonin and its receptors, and then discuss both molecular and epidemiological evidence on melatonin anticancer effects. Finally, we will shed light on potential cross-talk between melatonin signaling and the Hippo signaling pathway, along with the possible implications for cancer therapy.

Keywords: melatonin; cancer; melatonin receptors; GPCR signaling; Hippo pathway

1. Introduction

Melatonin (*N*-acetyl-5-methoxy tryptamine) is a pleiotropic neurohormone mainly secreted by the pineal gland and partially by other peripheral organs that are widely distributed, including in the gut, gonads, retina, and immune-competent cells [1]. Its production is tightly regulated by light/dark signals coming from the retina, following a circadian rhythm, with a peak during the night and relatively lower concentrations during the day, when the light turns off its production [2–4]. Melatonin peak levels are higher in new-borns and start to decline in the elderly [5].

The physiological input for pineal melatonin production starts in a subgroup of Retinal Ganglion Cells sensitive to a specific light-blue wavelength [2,3] that transmits information to the pineal gland through the retino-hypothalamic tract and induces the transcription and stabilization of *N*-acetyltransferase (NAT) enzyme [6,7]. This latter, together with the hydroxyindole-*O*-methyltransferase enzyme (HIOMT), is responsible for converting serotonin to melatonin [3,8,9]. During the day, light inhibits NAT and melatonin production [10].

Once produced, melatonin is released into the cerebrospinal fluid and capillaries and reaches all the body's tissues, with concentrations between picomolars and nanomolars. It is metabolized by the liver and secreted in the urine, where its major metabolite, 6-sulfatoxy-melatonin (aMT6s), correlates with melatonin's nocturnal plasma peaks [11–13]. Chronic exposure to artificial light at night deregulates melatonin levels, as shown in rodent models and in cohort studies of night-shift workers [14]. In addition, an inverse correlation between melatonin levels and tumor incidence has been reported in prospective nested case control studies [15–22], suggesting that supplementation with melatonin might be proposed as cancer chemopreventive treatment in human clinical studies [23–25].

2. Melatonin Membrane Receptors

Melatonin controls a plethora of physiological processes including regulation of sleep-wake rhythm, temperature and physiologic activities in the circadian clock, blood pressure regulation, stimulation of bone metabolism, immune function, reproductive functions, memory formation, cell differentiation and proliferation, inhibition of oxidative stress and inflammation processes [26–36]. All these functions employ both receptor-dependent and receptor-independent mechanisms. The two main membrane receptors, MTNR1A and MTRN1B, also known as MT1 and MT2, belong to the superfamily of G-protein coupled receptors (GPCRs), which constitute the largest family of membrane receptors with approximately 1000 members and respond to a wide variety of extracellular stimuli (hormones, neurotransmitters, or growth factors) controlling physiological processes such as cellular metabolism, secretion, cell differentiation, and growth [37]. MT1 and MT2 exist in both homo-dimeric and hetero-dimeric forms, and share high sequence homology [38]. They are expressed in several areas of the central nervous system (CNS), in the retina, the gastro-intestinal tract, arteries and immune cells [33]. They show different affinities for melatonin: MT2 has a 5-fold higher affinity than MT1, in both humans and other species [38–40]. MT3, a low affinity binding receptor, is a Quinone reductase 2, an enzyme that catalyzes the reduction of quinones into quinols having important implications on oxidative stress [41,42].

MT1 and MT2 Mediated Signal Transduction

Upon agonist binding, cytoplasmic heterotrimeric G proteins that are comprised of $G\alpha$, β and γ subunits dissociate from GPCR transmembrane receptors [43]. The 15 different $G\alpha$ subunits are classified into four families, $G\alpha_{12/13}$, $G\alpha_q/11$, $G\alpha_i/o$, and $G\alpha_s$ [44], which in turn act on individual effectors such as adenylate cyclase (AC), phosphodiesterase (PDE), phospholipase C (PLC), or ion channels to affect the levels of associated second messengers including 3',5'-cyclic adenosine or guanosine monophosphate (cAMP and cGMP), inositol triphosphate (IP_3), and calcium [45].

MT1 and MT2 receptors mainly associate with $G\alpha_i$ proteins and to a lesser extent with $G\alpha_q/11$ and $G\alpha_s$ proteins [46–55] which can couple to multiple signal transduction cascades, either alternately, or concomitantly in the same tissue [56]. In general, the signal transduction pathways induced by melatonin receptors are cell type and tissue specific [33] leading to unique cellular responses and suggesting a potential crosstalk with other signaling pathways. For example, MT1 receptor activation by melatonin may lead to different and in some cases opposite signaling pathways, depending on which $G\alpha$ protein is activated. In general, $G\alpha_i$ activation leads to the inhibition of the adenylyl cyclase activity with consequent inhibition of cyclic AMP (cAMP) formation, inhibition of protein kinase A (PKA) activity, and reduced phosphorylation and transcriptional activity of the cAMP-responsive element binding (CREB) as well as activation of phospholipase C β [48,57–64]. Conversely, in other systems such as Cos7 fibroblasts, HEK293 and MCF7 cells, activation of $G\alpha_q$ and $G\alpha_s$ proteins coupled to MT1 receptors leads to an increase of cAMP formation. Increased intracellular cAMP in turn activates PKA and PKC, which causes the inhibition of NF- κ B (Nuclear Factor Kappa-light-chain-enhancer of activated B cells) with consequent derepression of the oncosuppressor p27^{kip1} and attenuation of the androgen response in prostate cells [53–55,65–67], activation of JNK in Cos7 cells [68], and phosphorylation of ERK1/2 in HEK 293 cells [69].

3. Melatonin and Nuclear Receptors: Contrasting Evidence

In the 90's and a few years later, some studies showed that melatonin and its analogues can bind in vitro to nuclear receptors belonging to the family of retinoid Z receptor/Retinoid Orphan Receptor alpha (RZR/ROR α) [70–74]. These receptors are organized into the following structural domains: a N-terminal transactivating domain, a DNA-binding domain, a variable domain, and a ligand-binding domain [75]. Once activated, they bind ROR response elements (ROREs) on the chromatin (TAAA/TNTAGGTCA motif) primarily as monomers [76–79] and regulate genes

involved in cell differentiation, immune response, lipid metabolism, CNS development, tumour growth and inflammation [33,71–73,80–86]. Biologically, a role for melatonin in the downregulation of 5-lipoxygenase gene through RZR/ROR α receptors has been shown by Carlsberg's group in B lymphocytes [87]. However, Carlberg's group in 1997 retracted the report that melatonin is a direct ligand of these nuclear receptors because they could not reproduce their results. Yet, the above mentioned study suggested a positive regulation of RZR/ROR α by melatonin either in transcriptional activation or in repression of target genes [70–73,87], even if a direct binding of melatonin to receptors is arguable. In 2011, the group of Lardone and coworkers showed a direct interaction between melatonin and nuclear receptors in T lymphocytes and a negative regulation of nuclear ROR α levels by melatonin. Other works showed a possible negative regulation of RZR/ROR α by melatonin in different experimental systems [88,89], while in models of gastric cancer melatonin has been shown to negatively regulate RZR/ROR γ [90].

4. Oncoprotective Role of Melatonin: In Vitro Evidence

Epidemiological studies have suggested that melatonin decreases the risk of developing different types of cancer. Recently, the molecular mechanism by which melatonin exerts its anticancer effects has been revised [91,92]. This might occur either through downregulation of oncogenic pathways or via activation of tumor suppressor activities.

Melatonin can activate phosphorylation cascades, mediated by MEK1/2, ERK1/2, JNK and p38 MAPK, through binding to its membrane receptors MT1 and MT2 [93–97]. In particular, our group and others have shown that the binding of melatonin to MT1 and MT2 triggers a phosphorylation cascade, mediated in part by p38, which leads to the activation of p53 through phosphorylation of Ser15. This leads to a transient cell cycle arrest through the accumulation of tumor suppressive proteins (see Figure 1) and the induction of DNA repair mechanisms that prevent the accumulation of DNA mutations in response to DNA damage induced by chemotherapeutic agents or ionizing radiations. These events occurred both in normal and tumor cells only in the presence of intact MT1 and MT2 signaling [98–100].

Melatonin also causes the reduction of the abundance and the transcriptional activity of the NF- κ B (nuclear factor kappa-light-chain-enhancer of activated B cells) transcription factor, leading to reduced proliferation and metastasis as well as increased apoptosis in basal conditions or in response to chemotherapeutic agents in several models of cancer including breast cancer, prostate cancer, colon and gastric cancer, pancreatic cancer, renal carcinoma, and hepatoma [55,93,95,101–104]. Part of the inhibition of the NF- κ B transcriptional activity is elicited through the activation of JNK and p38 [93]. Oncosuppressive pathways induced by melatonin were also observed in vitro in glioblastoma [105,106] and osteosarcoma [107]. It is important to mention that beside its effects on cancer cells, melatonin protects from apoptosis normal cells like spermatozoa [108], cells in the liver [109], in the nervous [110] and immune systems [84,111–120], in which melatonin counteracts aging-related diseases, and stimulates immune cells activation and proliferation, respectively. Melatonin increases the number of effector T cells and decreases the number of regulative T cells (Tregs) [119,120]. Tregs have an inhibitory effect on anti-cancer immunity and some tumor cells are able to upregulate and recruit Tregs to escape the antitumor effect of the cellular immune system [121].

In summary, melatonin promotes apoptosis in certain circumstances, for example in cancer cells and in Treg cells, while it protects normal cells from apoptosis, including cells of the immune system that actively counteract infections and tumors.

The net effect of these opposite mechanisms is the protection of the whole organism from inflammation, aging-related diseases, cancer development, and progression.

Melatonin also inhibits cancer cell migration and invasiveness by increasing the expression of cell adhesion molecules [122–125] and by reducing the expression of the RhoA kinase ROCK involved in progression and metastasization of several tumors [124,126,127].

Moreover, melatonin has been shown to inhibit the expression of stemness-related genes, [105,128,129] to inhibit stemness-related pathways [105,106] to improve the response to several anticancer therapies [102,103,130–134], and to inhibit angiogenesis [127,135–146]. Finally, in Androgen Receptor (AR) and Estrogen Receptor (ER) positive cells, melatonin inhibits the AR [54,65,147–149] and ER response [128,150–153] through different mechanisms either mediated by MT1 or independent of MT1 receptor binding.

In general, MT1 seems to play a prominent role in triggering anti-tumor cellular responses mediated by melatonin [53–55,154–159], although in some experimental models MT2 has been shown to be required too [160,161].

Melatonin can also counteract tumor formation through mechanisms independent of MT1 and MT2. For example, through calmodulin (CaM) binding, melatonin interferes with the transcription of Estrogen Receptor α (ER α) genes in response to estrogen (E₂). The formation of a melatonin–CaM complex, in fact, impairs the formation of a proper E₂–ER α –CaM complex on ER α targets [153]. Moreover, in models of colon cancer, gastric cancer [82,90,162,163], and ovarian carcinoma [164], nuclear RZR/ROR receptors were proposed to contribute to the tumor-suppressive effects of melatonin even if, as mentioned above, a direct interaction between melatonin and RZR/ROR α receptors is still a matter of debate because no one has yet reproduced Carlberg et al.’s pioneering results that show a direct interaction between melatonin and nuclear receptors (Figure 1).




Figure 1. Oncosuppressive mechanisms mediated by melatonin. Melatonin (MLT) signaling has been shown to reduce the abundance and transcriptional activity of the NF- κ B (nuclear factor kappa-light-chain-enhancer of activated B cells) transcription factor as well as to activate phosphorylation cascades mediated by mitogen-activated protein kinases (MAPKs) such as MEK1/2, ERK1/2, JNK, and p38. Both NF- κ B inhibition and MAPKs activation in turn inhibit cell growth and motility, and promote apoptosis and DNA damage repair through mechanisms involving the accumulation of oncosuppressors such as p53, p27^{kip1}, and p21, activation of DNA repair complexes such as P53/PML/H2AX on DNA damage sites, and transcriptional control of genes involved in the cell cycle, apoptosis, and invasiveness. Even though it is still a matter of debate, there is the possibility that melatonin can also bind to nuclear receptors RZR/ROR, controlling the transcription of RORE (ROR response Elements) on genes of the retinoic acid response, among which are several genes controlling cell cycle progression and cell growth (p21, 5-lipoxygenase, and others). Finally, melatonin can bind to the intracellular protein calmodulin (CaM) and reduce the Estrogen Receptor α (ER α) response in ER positive cells by impairing the formation of a proper E₂–ER α –CaM complex on Estrogen Receptor Elements (EREs) on target genes. Arrows indicate activation, while dashed and blunt lines indicate inhibition. Activation indicates an increase in protein or activity levels, while inhibition indicates a decrease in protein or activity levels.

5. Melatonin Antioxidant Properties

Melatonin is an antioxidant, anti-inflammatory and anti-angiogenic molecule. Various oxidative reactions normally occurring in the organism, mainly in mitochondria, generate free radicals from reactive oxygen species (ROS) and reactive nitrogen species (RNS). In normal cells, these species are required for signal transduction before their elimination through endogenous antioxidant compounds and enzymes. The aberrant accumulation of reactive oxidant species can cause multiple lesions in macromolecules (nucleic acids, proteins, and lipids), leading to their damage. In cancer the aberrant activation of pathways leading to cell proliferation and invasiveness causes a hyperaccumulation of ROS and RNS. Endogenous antioxidants are not sufficient to counteract this accumulation. However, cancer cells often acquire resistance to oxidative stress and escape free radical damage. In that context, ROS accumulation in turn promotes tumor development and progression and induces increased cell proliferation, evasion of apoptosis, tissue invasion-metastasis, and angiogenesis (reviewed in [165,166]).

Melatonin counteracts the oxidative stress through multiple mechanisms [167]. It stimulates the expression and activity of antioxidative enzymes [168]. It inhibits the expression of QR2 enzyme at pharmacological concentrations that are higher than those required for MT1 and MT2 activation. Given that QR2 reduces quinones into quinols, and thereby functions as an indirect producer of ROS, it has been proposed that the inhibition of QR2 activity may in part explain the antioxidant properties of melatonin [42].

Moreover, melatonin preserves the integrity and the function of the mitochondria [169–171]. Through these mechanisms, melatonin prevents the genotoxic and carcinogenic effects of oxidative stress and helps to maintain cell function and survival.

6. Clinical Studies

Melatonin is involved in several physiological processes, and its deficiency (or an altered expression of its receptors) has been associated with a number of chronic diseases including several types of cancer [172–176]. Conversely, a number of randomized and controlled clinical trials showed that exogenously administered melatonin has, among several biological effects, anti-cancer, anti-inflammatory and antioxidant properties in different cancer types, thus improving the responses of patients to traditional therapies and reducing the side effects of the latter [23–25].

In the following section, we will present results from observational, translational and cohort prospective studies on the association between pre-diagnostic prolonged exposure to daylight and low melatonin serum levels and subsequent cancer development.

6.1. Circadian Disruption and Increased Light Exposure Contribute to Increased Cancer Risk

In 1991 [177], Hann and co-workers showed a reduced risk of breast cancer in blind women. Based on the observation that blind women are constantly in the dark and that melatonin production is increased during the night [178], this study suggested for the first time a possible protective role of melatonin in blind women against the risk of developing cancer. Later observations supported this hypothesis [179–181]. Conversely, several bodies of evidence showed that disruption of the circadian rhythm, in part as a consequence of night-shift work and light pollution at night (LAN), increases the risk of developing breast cancer [182–184] and prostate cancer [185]. Importantly, our group and others showed an inverse correlation between night work, circadian disruption and melatonin production suggesting a protective role of melatonin against diseases associated with circadian disruption [35].

6.2. Low Levels of Endogenous Melatonin or Altered Expression of Its Receptors Are Associated with Increased Cancer Risk

Many groups, including ours, showed that high levels of endogenous melatonin measured many years before the onset of breast cancer were associated with a reduction of breast cancer

occurrence [15,16]. Other sets of evidence suggested a protective role of circulating melatonin on prostate cancer development [17].

Conversely, two recent translational studies showed a lower expression of MT1 and MT2 receptors in colon cancer tissues compared to matched normal tissues, suggesting melatonin's protective role in colon cancer development [159,160]. A negative correlation between melatonin receptor expression and cancer has also been observed in Oral Squamous Cell Carcinoma (OSCC), where a reduced expression of MT1 is also related to the T stage of tumor [186], and in breast cancer, where a lower MT1 expression is associated with a poorer prognosis [156], together with a higher tumor grade and TNM staging [187]. Finally, in Renal Cell Carcinoma (RCC) MT1 receptor expression was found to be lower in cancer tissue compared to normal tissue [104].

7. A Possible Crosstalk between Melatonin Signaling and the Hippo Tumor Suppressor Pathway

As mentioned above, melatonin signals in part through MT1 and MT2 GPCR receptors. Recently, GPCR signaling has been shown to regulate the Hippo pathway, which controls animal organ development and growth and whose dysregulation is often involved in tumorigenesis (reviewed in [188]). Components of the Hippo pathway include membrane-associated proteins that sense cell polarity, cell density, and mechanical and metabolic cues that in turn activate a cascade of kinases with adaptor proteins whose final targets are the transcriptional coactivators YAP and TAZ. YAP/TAZ work as oncogenes in many solid cancers, where they are often upregulated or hyperactivated compared to normal tissues (reviewed in [188]).

When the Hippo cascade is on, phosphorylation of YAP and TAZ by LATS1/2 kinases results in their nuclear export, cytoplasmic retention [189–194], and degradation by the proteasome [195–197]. When the Hippo cascade is off, YAP/TAZ are dephosphorylated and are able to exert their nuclear function and promote transcription of oncogenes in association with oncogenic transcription factors such as TEADs, SMADs, and others [188].

Since YAP/TAZ are becoming increasingly attractive and promising therapeutic targets in cancer treatment (reviewed in [198]), much importance is being placed on the discovery and characterization of inhibitors of YAP/TAZ oncogenic function. What is melatonin's role in this scenario? At present, no literature has been produced on this topic. However, numerous independent sets of evidence suggest a potential antagonism between melatonin signaling and YAP/TAZ oncogenic function; we will try to summarize them in the following sections.

7.1. *G α s May Be a Common Molecular Intermediate between Melatonin Signaling and GPCR/YAP/TAZ Signaling*

GPCR signaling regulates YAP/TAZ in response to several biochemical stimuli and YAP/TAZ can be either activated or inhibited depending on which GPCR and subsequent G α protein is activated. For example, LPA, S1P, and thrombin activate G α_i , G α_q , and G $\alpha_{12/13}$, which, in turn, activate YAP/TAZ by inducing their dephosphorylation mediated by Protein Phosphatase 1A (PP1A) and by repressing LATS1/2 kinase activity. This mechanism requires the Rho GTPase RhoA and its associated kinase ROCK and results in YAP/TAZ nuclear translocation [199–203]. In contrast, glucagon, epinephrine, and dobutamine, which transmit signal from G α_s , inhibit YAP/TAZ. One of the proposed mechanisms mediated by G α_s is an increased intracellular cAMP that leads to the activation of protein kinase A (PKA). This in turn inhibits the RhoA/ROCK signaling and stimulates LATS1/2 to phosphorylate YAP/TAZ, which are sequestered in the cytoplasm [203–205]. The inhibitory effect of cAMP accumulation on oncogenic YAP/TAZ is conserved in different cell lines, including breast metastatic MDA-MB-231, U2OS, MCF10A, HEK293A, and mouse embryonic fibroblasts (MEFs) [205].

Similarly, melatonin has been shown to activate G α_s proteins associated with MT1 receptors in prostate cell lines [53–55,65–67], Cos-7 cells [68], and HEK293 cells [69], as well as to increase intracellular cAMP with subsequent activation of PKA and PKC. Thus, the activation of PKA and PKC mediated by G α_s in response to different stimuli (glucagon, epinephrine, dobutamine, melatonin)

may lead to inhibition of cell proliferation and invasiveness through multiple converging mechanisms, including LATS1/2 activation [203–205] and, as mentioned above, inhibition of NF- κ B transcriptional activity and inhibition of the AR response in AR positive cells [55]. Moreover, a recent study showed that TAZ promoter is directly targeted and activated by NF- κ B [206] suggesting that melatonin may potentially inhibit YAP/TAZ pro-oncogenic function either through increasing LATS1/2 activity (following PKA and PKC activation) or reducing TAZ transcription (following NF- κ B inhibition) (Figure 2).




Figure 2. Interplay between G-Protein Coupled Receptors (GPCR) signaling regulated by melatonin and GPCR signaling regulating YAP/TAZ. MT1 binding by melatonin (MLT) induces activation of associated G α q and G α s that leads to the accumulation of intracellular cAMP that in turn activates Protein Kinase A (PKA) and PKC. These in turn inhibit NF- κ B transcriptional activity on its target promoters, including TAZ promoter. In Androgen Receptor (AR) positive cells, PKA and PKC inhibit the androgen response on AR responsive genes. In parallel, glucagon, epinephrine, and dobutamine signal through G α s, inducing increased intracellular cAMP and activation of PKA. This in turn inhibits the RhoGTPase RhoA and activates LATS1/2 kinases, resulting in phosphorylation of YAP/TAZ, their cytoplasmic sequestration by 14-3-3 protein, their degradation mediated by β TrCP, and the impairment of their nuclear activity on pro-proliferative, pro-metastatic, and anti-apoptotic genes. \uparrow indicates an increase in protein levels or activity; \downarrow indicates a decrease in protein levels or activity.

7.2. Metabolic Pathways: Antagonism between Melatonin and YAP/TAZ

Beyond GPCR signaling, YAP/TAZ are also regulated by cell-cell contact, mechanical forces, and metabolic cues. These induce specific intracellular signaling affecting YAP/TAZ function through Hippo kinase cascade-dependent and independent mechanisms. Before going into more detail, some of these mechanisms may crosstalk with melatonin signaling. In general, we hypothesize an antagonism between melatonin and YAP/TAZ on multiple mechanisms involved in tumorigenesis.

Insulin, insulin-like growth factors (IGF-I), nutrient intake, and other growth factors upregulate cellular biosynthetic pathways to sustain cellular growth and proliferation through the activation of protein kinases AKT/PI3K and mammalian target of rapamycin (mTOR) [207–211]. It has recently been shown that insulin and GPCR signaling engage in crosstalk and synergize to positively regulate YAP nuclear function onto YAP/TEAD target genes in pancreatic ductal adenocarcinoma (PDAC) cells via PI3K activation [212]. YAP has been shown in turn to positively regulate the insulin and the IGF-1 signaling [213] to drive IGF-2 expression, activate mTOR signaling and AKT [214–216], promote glucose uptake and glycolysis [217], driving growth advantage, metastatic competence,

angiogenesis, and therapy resistance in various model systems. On the other hand, melatonin was shown to inhibit AKT/mTOR signaling in models of ovarian cancer [104], breast cancer [218], hepatoma [219], and melanoma [220], where AKT/mTOR are aberrantly hyperactivated and contribute to carcinogenesis [221]. Moreover, melatonin decreases insulin production from pancreatic β cells while increasing the expression and secretion of glucagon from pancreatic α cells [222]. Since glucagon is a negative regulator of YAP/TAZ nuclear function, as mentioned above, melatonin may indirectly inhibit nuclear YAP/TAZ through glucagon upregulation.

Interestingly, AKT and the Insulin Receptor Scaffold 4 (IRS4) have been shown to co-purify with MT2 receptor by Daulat and co-workers [223–225].

Together, this body of evidence suggests potential cross-talk between melatonin signaling, Hippo signaling, and insulin–glucagon signaling, in agreement with a growing literature that showing a reciprocal regulation between YAP/TAZ and metabolism on the one hand [226] and between melatonin and metabolism on the other [227,228] (Figure 3).




Figure 3. Interplay between melatonin, YAP/TAZ, and metabolic pathways. Melatonin (MLT) upregulates glucagon production and downregulates insulin production and signaling. Glucagon inhibits YAP/TAZ nuclear function through G α s signaling. Conversely, insulin and GPCR signaling synergize to positively regulate nuclear YAP onto YAP/TEAD target genes. In addition, YAP/TAZ activate AKT and mTOR, which are part of the insulin signaling. In conclusion, melatonin may inhibit YAP/TAZ nuclear function by inducing glucagon expression and decreasing insulin expression. On the other hand, YAP/TAZ positively regulate insulin signaling, and, vice versa, insulin signaling positively regulates YAP, suggesting an antagonism between melatonin function and nuclear YAP/TAZ function. Arrows indicate activation, while dashed and blunt lines indicate inhibition. The figure also shows the interaction between the insulin receptor scaffold 4 (IRS4) with insulin receptor, integrins, and MT1/2 receptors potentially linking these transmembrane proteins at the cell membrane. IR = Insulin Receptor, IRS1/2/4 = insulin receptor scaffold 1/2/4.

7.3. Mechanotransduction and Chemoresistance: Opposite Roles of Melatonin and YAP/TAZ

Mechanotransduction is a process where mechanical forces coming from the extracellular matrix (ECM) and from the cytoskeleton are transduced into cellular biochemical signals to regulate cell growth and survival. YAP/TAZ are widely recognized mechanotransducers and mechanoeffectors. They are preferentially active in the nucleus when cells are grown at low density, or on a stiff extracellular substrate, conditions where the cell–ECM contact area is larger and the cytoskeleton is subjected to a stronger mechanical stimulation (often the case of a tumor

microenvironment). Conversely, YAP/TAZ effectors translocate to the cytoplasm in response to high cellular density/cell contact, or on a soft extracellular substrate, where the cell experiences lower mechanical stress [189,229–237]. Once activated, YAP/TAZ are able to regulate genes involved in extracellular matrix remodelling [238,239]. Matrix rigidity plays an important role in tumor development because it changes during tumorigenesis and regulates cell proliferation, stemness, and invasiveness, and also the response of cancer cells to various chemotherapy agents, through different pathways including YAP and TAZ regulation among others [240–243]. Accordingly, a role for YAP/TAZ in increasing the resistance of cancer cells to various chemotherapy agents has been extensively documented [243–248]. Conversely, melatonin treatment has been shown to partially overcome resistance to chemotherapy, suggesting a possible antagonism between melatonin and YAP/TAZ in cancer chemoresistance [24,102,103,130–134]. In response to mechanical stress, the stabilization of cytoskeletal F-actin fibers and the activation of RhoA–ROCK facilitate YAP/TAZ nuclear translocation, while F-actin destabilization induces YAP/TAZ phosphorylation and cytoplasmic retention. Currently, the gap between YAP/TAZ and these upstream transducers remains to be filled and it would be interesting to see what role melatonin signaling may play in this process. Some bodies of evidence suggest melatonin's role in mechanotransduction: melatonin has been shown to regulate cytoskeletal dynamics *in vitro* [249–251] and *in vivo* [252,253], and to reduce the expression of the RhoA kinase ROCK [124,126,127]. Moreover, Daulat and coworkers characterized several proteins interacting with MT1 and MT2, among which is Filamin A [223–225], an actin-binding protein that contributes to the cross-linking of cortical actin filaments into a dynamic three-dimensional structure and is involved in mechanotransduction [254].

Akbarzadeh and co-workers' recent work showed that ovarian cancer cells responded differently to melatonin treatment (in terms of cell proliferation, morphological changes, and stemness) depending on the composition of the extracellular matrix where they were cultured [145]. In this work, the authors showed for the first time the role played by mechanical cues in regulating the response of cells to melatonin.

7.4. Cell Contact/Polarity and RhoA/ROCK Signaling

Epithelial tissues line the surface of the animal body and internal cavities. They are composed of cells oriented in the space with an apical-basal polarity. Several proteins contribute to the proper cell-cell adhesion, orientation and spatial organization within the tissue and their dysregulation can promote tumor development and metastasization [255–257]. In general, proteins involved in cell contact/junction and cell polarity negatively regulate YAP/TAZ nuclear function by sequestering YAP/TAZ at the apical plasma membrane, thus excluding them from the nucleus, and by interacting with and activating Hippo pathway core kinases [195,255,258–272]. Catenin $\delta 1$ (p120 catenin), a scaffold protein linking cytoskeletal actin fibers to adherens junctions at the plasma membrane, has been co-purified with MT1 and MT2 by Daulat and co-workers [223–225]. p120 has been shown to inhibit nuclear YAP and TAZ when localized at cellular junctions through inhibition of RhoA–ROCK signaling [273–276], as well as to stabilize cell adhesion cadherin complexes [277–279] that negatively regulate YAP/TAZ nuclear function [270,280]. Melatonin by itself reduces the migration and invasiveness of different cancer types by increasing the expression of E-cadherin and other adhesion molecules [122–125] and by reducing the expression of the RhoA kinase ROCK [124,126,127]. Rac1, a Rho GTPase that can functionally counteract RhoA [281,282], and the Ras-related GTPase Rap1 that activates Rac1 [283], have been co-purified with MT1 [223]. Together, this body of evidence suggests a possible role of melatonin and proteins associated with their receptors in the inhibition of the YAP/TAZ pro-oncogenic and metastatic function, through the inhibition of RhoA–ROCK signaling and via the stabilization of cell surface adhesion proteins [256].

Moreover, the MT1 receptor has been shown to interact with PDZ domain proteins including MUPP1 and the neuronal NO synthase (NOS) [225,284,285], while MT2 has been co-purified with 14-3-3 protein [223]. MUPP1 is concentrated at tight junctions at the apical membrane and, together

with ZO-1 and other scaffold proteins, anchors the integral proteins of tight junctions to the F-actin cytoskeleton and contributes to their correct function and localization [286]. TAZ, containing a PDZ-binding motif, has been shown to interact both with ZO-1 and 14-3-3, which tether TAZ at the plasma membrane, thus inhibiting its nuclear function [189,192,193,268]. Also $G\alpha i2$, $G\alpha o$, and $G\alpha 12$ have been shown to interact with ZO-1 in different systems and regulate tight junction assembly and permeability [287,288], while MUPP1 has been shown to promote $G\alpha i$ coupling and signaling of the MT1 receptor [268,285]. Recently, YAP has been found in complex with the nitric oxide synthase 1 adaptor protein (NOS1AP) at cell-cell contacts together with the Scribble polarity complex [289,290], a negative regulator of YAP/TAZ pro-oncogenic function [245,291]. This interaction increases YAP phosphorylation and cytoplasmic sequestration. Interestingly, MT1 has been co-purified with the nitric oxide synthase (NOS). All these sets of evidence suggest a structural and functional role of cell polarity and cell contact proteins in the regulation of both the Hippo pathway and GPCR/MT1/MT2 signaling, which may converge in the inhibition of YAP/TAZ nuclear function. All these interactions are schematically represented in Figure 4.




Figure 4. Interplay between melatonin signaling, cell contact-cell polarity complexes, mechanotransduction, and YAP/TAZ. Melatonin signaling inhibits RhoA/ROCK and increases the expression of cell surface adhesion molecules such as E-cadherin. This suggests that it may inhibit YAP/TAZ nuclear function, which in turn is promoted by RhoA/ROCK and inhibited by cell adhesion molecules. P120 catenin has been co-purified with MT1/MT2 receptors. When localized at the plasma membrane, it stabilizes E-cadherin at the adherens junction (AJ) while inhibiting RhoA–ROCK, thus inhibiting nuclear YAP/TAZ (Y/T). MT1/2 also co-purified with MUPP1 scaffold protein, which interacts with ZO-1 at tight junctions (TJ). Moreover, several studies showed that ZO-1 binds $G\alpha$ proteins. This suggests a possible interaction with TAZ, which has been demonstrated to be sequestered at the plasma membrane through its interaction with ZO-1 at tight junctions. Moreover, YAP/TAZ may be sequestered at the plasma membrane by the 14-3-3 protein, which has been co-purified with MT1 and MT2. MT1/2 have also been co-purified with filaminA, involved in mechanotransduction, suggesting a link between melatonin receptor signaling and mechanotransduction, which has been demonstrated to regulate YAP/TAZ function and to be in turn controlled by YAP/TAZ. Finally, YAP has been co-purified with NOS1AP (nitric oxide synthase1 adaptor protein) in the complex formed with the scribble polarity proteins in proximity to cell–cell contacts. As NOS (nitric oxid syntase) has been co-purified with MT1/MT2, this again may suggest a possible indirect interaction of YAP with MT1/MT2 at the plasma membrane. In general, YAP/TAZ sequestration at the plasma membrane prevents their nuclear pro-proliferative function. Arrows indicate activation, while dashed and blunt lines indicate inhibition.

7.5. Opposite Roles of YAP/TAZ and Melatonin in Androgen–Estrogen Receptor Response and Angiogenesis

Melatonin inhibits the proliferation of Estrogen Receptor α (ER α)-positive lines more efficiently than ER α -negative lines, suggesting that part of its antiproliferative effect is mediated by the inhibition of the estrogen response. In fact, melatonin is able to inhibit the synthesis of steroids as well as interfere with the binding of the ER to its target genes [128,150–153]. Conversely, other studies showed that melatonin signaling is modulated by antiestrogens in breast and ovarian cancer cells [292]. Similarly, melatonin inhibits Androgen Receptor (AR) response in normal and malignant prostate epithelial cells [147–149]. On the other hand, LATS1/2 kinases have been shown to attenuate the androgen response in the prostate by inhibiting AR chromatin binding and transcriptional activity [293] as well as promoting ER degradation and reduction of its transcriptional activity in the breast [294,295], suggesting that melatonin signaling and Hippo signaling may converge to inhibit the ER and AR response.

Finally, melatonin inhibits angiogenesis by interfering with its Hif1 α - and STAT3-mediated transcription of VEGF [127,135–146]. Conversely, YAP stabilizes H1F1 α in response to hypoxia [296], suggesting an antagonistic role of melatonin and YAP/TAZ in angiogenesis regulation.

8. Conclusions

At present, promising preclinical and clinical studies suggest that melatonin may be a safe and valid therapy for the treatment of several types of malignancies when administered concomitantly with traditional therapies. In fact, melatonin has been shown to improve the response of patients to different therapies while reducing their toxic effects. On the other hand, preclinical studies showed that inhibitors of YAP/TAZ associated with traditional therapies reduce tumor growth as well as radio- and chemoresistance in different types of cancers [198,215,243,245–248,297]. To our knowledge, functional crosstalk between melatonin signaling and Hippo/YAP/TAZ signaling has never been previously addressed in the literature. However, several experimental observations may suggest that both the melatonin signaling and Hippo signaling pathways may intersect at different levels (GPCR signaling, AKT/PI3K signaling, and mechanotransduction) and both may potentially inhibit the oncogenic function of YAP and TAZ through many converging mechanisms. Although these potential cross-talks need extensive experimental validation, they may open up a new field of investigation with important implications for (1) a better understanding of melatonin- and YAP/TAZ-mediated pathways, which are still not completely elucidated; and (2) the potential design of novel combinatorial cancer treatments. Today, in fact, the use of pharmacological inhibitors of YAP/TAZ is still in the preclinical phase, while melatonin is used in clinic in combination with other traditional therapies. Studies in this new direction might be worth pursuing.

Acknowledgments: The work has been supported by Aboca and Associazione Aurora Tomaselli to Sabrina Strano, and by the ArceloMittal Dofasco Company to Paola Muti.

Author Contributions: Federica Lo Sardo wrote the manuscript; Paola Muti contributed to the introduction and the clinical aspects of melatonin and provided indication about the organization of the manuscript; Sabrina Strano and Giovanni Blandino supervised and corrected the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Acuna-Castroviejo, D.; Escames, G.; Venegas, C.; Diaz-Casado, M.E.; Lima-Cabello, E.; Lopez, L.C.; Rosales-Corral, S.; Tan, D.X.; Reiter, R.J. Extrapineal melatonin: Sources, regulation, and potential functions. *Cell. Mol. Life Sci.* **2014**, *71*, 2997–3025. [[CrossRef](#)] [[PubMed](#)]
2. Dominguez-Solis, C.A.; Perez-Leon, J.A. Phototransduction mediated by melanopsin in intrinsically photosensitive retinal ganglion cells. *Gac. Med. Mex.* **2015**, *151*, 764–776. [[PubMed](#)]
3. Berson, D.M.; Dunn, F.A.; Takao, M. Phototransduction by retinal ganglion cells that set the circadian clock. *Science* **2002**, *295*, 1070–1073. [[CrossRef](#)] [[PubMed](#)]

4. Reiter, R.J. The melatonin rhythm: Both a clock and a calendar. *Experientia* **1993**, *49*, 654–664. [[CrossRef](#)] [[PubMed](#)]
5. Hardeland, R. Melatonin in aging and disease—Multiple consequences of reduced secretion, options and limits of treatment. *Aging Dis.* **2012**, *3*, 194–225. [[PubMed](#)]
6. Karolczak, M.; Korf, H.W.; Stehle, J.H. The rhythm and blues of gene expression in the rodent pineal gland. *Endocrine* **2005**, *27*, 89–100. [[CrossRef](#)]
7. Klein, D.C. Arylalkylamine N-acetyltransferase: “The timezyme”. *J. Biol. Chem.* **2007**, *282*, 4233–4237. [[CrossRef](#)] [[PubMed](#)]
8. Bernard, M.; Guerlotte, J.; Greve, P.; Grechez-Cassiau, A.; Iuvone, M.P.; Zatz, M.; Chong, N.W.; Klein, D.C.; Voisin, P. Melatonin synthesis pathway: Circadian regulation of the genes encoding the key enzymes in the chicken pineal gland and retina. *Reprod. Nutr. Dev.* **1999**, *39*, 325–334. [[CrossRef](#)] [[PubMed](#)]
9. Klein, D.C.; Moore, R.Y. Pineal N-acetyltransferase and hydroxyindole-O-methyltransferase: Control by the retinohypothalamic tract and the suprachiasmatic nucleus. *Brain Res.* **1979**, *174*, 245–262. [[CrossRef](#)]
10. Gastel, J.A.; Roseboom, P.H.; Rinaldi, P.A.; Weller, J.L.; Klein, D.C. Melatonin production: Proteasomal proteolysis in serotonin N-acetyltransferase regulation. *Science* **1998**, *279*, 1358–1360. [[CrossRef](#)] [[PubMed](#)]
11. Grof, E.; Grof, P.; Brown, G.M.; Arato, M.; Lane, J. Investigations of melatonin secretion in man. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **1985**, *9*, 609–612. [[CrossRef](#)]
12. Graham, C.; Cook, M.R.; Kavet, R.; Sastre, A.; Smith, D.K. Prediction of nocturnal plasma melatonin from morning urinary measures. *J. Pineal Res.* **1998**, *24*, 230–238. [[CrossRef](#)] [[PubMed](#)]
13. Schernhammer, E.S.; Rosner, B.; Willett, W.C.; Laden, F.; Colditz, G.A.; Hankinson, S.E. Epidemiology of urinary melatonin in women and its relation to other hormones and night work. *Cancer Epidemiol. Biomark. Prev.* **2004**, *13*, 936–943.
14. Reiter, R.J.; Tan, D.X.; Korkmaz, A.; Erren, T.C.; Piekarski, C.; Tamura, H.; Manchester, L.C. Light at night, chronodisruption, melatonin suppression, and cancer risk: A review. *Crit. Rev. Oncog.* **2007**, *13*, 303–328. [[CrossRef](#)] [[PubMed](#)]
15. Yang, W.S.; Deng, Q.; Fan, W.Y.; Wang, W.Y.; Wang, X. Light exposure at night, sleep duration, melatonin, and breast cancer: A dose-response analysis of observational studies. *Eur. J. Cancer Prev.* **2014**, *23*, 269–276. [[CrossRef](#)] [[PubMed](#)]
16. Basler, M.; Jetter, A.; Fink, D.; Seifert, B.; Kullak-Ublick, G.A.; Trojan, A. Urinary excretion of melatonin and association with breast cancer: Meta-analysis and review of the literature. *Breast Care* **2014**, *9*, 182–187. [[CrossRef](#)] [[PubMed](#)]
17. Shiu, S.Y.W. Towards rational and evidence-based use of melatonin in prostate cancer prevention and treatment. *J. Pineal Res.* **2007**, *43*, 1–9. [[CrossRef](#)] [[PubMed](#)]
18. Bartsch, C.; Bartsch, H.; Jain, A.K.; Laumas, K.R.; Wetterberg, L. Urinary melatonin levels in human breast cancer patients. *J. Neural Transm.* **1981**, *52*, 281–294. [[CrossRef](#)] [[PubMed](#)]
19. Tamarkin, L.; Danforth, D.; Lichter, A.; DeMoss, E.; Cohen, M.; Chabner, B.; Lippman, M. Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer. *Science* **1982**, *216*, 1003–1005. [[CrossRef](#)] [[PubMed](#)]
20. Schernhammer, E.S.; Berrino, F.; Krogh, V.; Secreto, G.; Micheli, A.; Venturelli, E.; Sieri, S.; Sempes, C.T.; Cavalleri, A.; Schunemann, H.J.; et al. Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women. *J. Natl. Cancer Inst.* **2008**, *100*, 898–905. [[CrossRef](#)] [[PubMed](#)]
21. Schernhammer, E.S.; Berrino, F.; Krogh, V.; Secreto, G.; Micheli, A.; Venturelli, E.; Grioni, S.; Sempes, C.T.; Cavalleri, A.; Schunemann, H.J.; et al. Urinary 6-sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: The ordet cohort. *Cancer Epidemiol. Biomark. Prev.* **2010**, *19*, 729–737. [[CrossRef](#)] [[PubMed](#)]
22. Devore, E.E.; Warner, E.T.; Eliassen, A.H.; Brown, S.B.; Beck, A.H.; Hankinson, S.E.; Schernhammer, E.S. Urinary melatonin in relation to postmenopausal breast cancer risk according to melatonin 1 receptor status. *Cancer Epidemiol. Biomark. Prev.* **2017**, *26*, 413–419. [[CrossRef](#)] [[PubMed](#)]
23. Wang, Y.M.; Jin, B.Z.; Ai, F.; Duan, C.H.; Lu, Y.Z.; Dong, T.F.; Fu, Q.L. The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: A meta-analysis of randomized controlled trials. *Cancer Chemother. Pharmacol.* **2012**, *69*, 1213–1220. [[CrossRef](#)] [[PubMed](#)]

24. Seely, D.; Wu, P.; Fritz, H.; Kennedy, D.A.; Tsui, T.; Seely, A.J.; Mills, E. Melatonin as adjuvant cancer care with and without chemotherapy: A systematic review and meta-analysis of randomized trials. *Integr. Cancer Ther.* **2012**, *11*, 293–303. [[CrossRef](#)] [[PubMed](#)]
25. Ernst, E.; Schmidt, K.; Baum, M. Complementary/alternative therapies for the treatment of breast cancer. A systematic review of randomized clinical trials and a critique of current terminology. *Breast J.* **2006**, *12*, 526–530. [[CrossRef](#)] [[PubMed](#)]
26. Armstrong, S.M. Melatonin and circadian control in mammals. *Experientia* **1989**, *45*, 932–938. [[CrossRef](#)] [[PubMed](#)]
27. Comai, S.; Gobbi, G. Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: A novel target in psychopharmacology. *J. Psychiatry Neurosci.* **2014**, *39*, 6–21. [[CrossRef](#)] [[PubMed](#)]
28. Fernando, S.; Rombauts, L. Melatonin: Shedding light on infertility?—A review of the recent literature. *J. Ovarian Res.* **2014**, *7*, 98. [[CrossRef](#)] [[PubMed](#)]
29. Grossman, E.; Laudon, M.; Yalcin, R.; Zengil, H.; Peleg, E.; Sharabi, Y.; Kamari, Y.; Shen-Orr, Z.; Zisapel, N. Melatonin reduces night blood pressure in patients with nocturnal hypertension. *Am. J. Med.* **2006**, *119*, 898–902. [[CrossRef](#)] [[PubMed](#)]
30. Korkmaz, A.; Reiter, R.J.; Topal, T.; Manchester, L.C.; Oter, S.; Tan, D.X. Melatonin: An established antioxidant worthy of use in clinical trials. *Mol. Med.* **2009**, *15*, 43–50. [[PubMed](#)]
31. Mathes, A.M. Hepatoprotective actions of melatonin: Possible mediation by melatonin receptors. *World J. Gastroenterol.* **2010**, *16*, 6087–6097. [[CrossRef](#)] [[PubMed](#)]
32. Moriya, T.; Horie, N.; Mitome, M.; Shinohara, K. Melatonin influences the proliferative and differentiative activity of neural stem cells. *J. Pineal Res.* **2007**, *42*, 411–418. [[CrossRef](#)] [[PubMed](#)]
33. Pandi-Perumal, S.R.; Trakht, I.; Srinivasan, V.; Spence, D.W.; Maestroni, G.J.; Zisapel, N.; Cardinali, D.P. Physiological effects of melatonin: Role of melatonin receptors and signal transduction pathways. *Prog. Neurobiol.* **2008**, *85*, 335–353. [[CrossRef](#)] [[PubMed](#)]
34. Strassman, R.J.; Qualls, C.R.; Lisansky, E.J.; Peake, G.T. Elevated rectal temperature produced by all-night bright light is reversed by melatonin infusion in men. *J. Appl. Physiol.* **1991**, *71*, 2178–2182. [[PubMed](#)]
35. Touitou, Y.; Reinberg, A.; Touitou, D. Association between light at night, melatonin secretion, sleep deprivation, and the internal clock: Health impacts and mechanisms of circadian disruption. *Life Sci.* **2017**, *173*, 94–106. [[CrossRef](#)] [[PubMed](#)]
36. Vriend, J.; Reiter, R.J. Melatonin, bone regulation and the ubiquitin-proteasome connection: A review. *Life Sci.* **2016**, *145*, 152–160. [[CrossRef](#)] [[PubMed](#)]
37. Pavlos, N.J.; Friedman, P.A. GPCR signaling and trafficking: The long and short of it. *Trends Endocrinol. Metab.* **2017**, *28*, 213–226. [[CrossRef](#)] [[PubMed](#)]
38. Liu, J.; Clough, S.J.; Hutchinson, A.J.; Adamah-Biassi, E.B.; Popovska-Gorevski, M.; Dubocovich, M.L. MT1 and MT2 melatonin receptors: A therapeutic perspective. *Annu. Rev. Pharmacol. Toxicol.* **2016**, *56*, 361–383. [[CrossRef](#)] [[PubMed](#)]
39. Legros, C.; Devavry, S.; Caignard, S.; Tessier, C.; Delagrangé, P.; Ouvry, C.; Boutin, J.A.; Nosjean, O. Melatonin MT(1) and MT(2) receptors display different molecular pharmacologies only in the G-protein coupled state. *Br. J. Pharmacol.* **2014**, *171*, 186–201. [[CrossRef](#)] [[PubMed](#)]
40. Jockers, R.; Delagrangé, P.; Dubocovich, M.L.; Markus, R.P.; Renault, N.; Tosini, G.; Cecon, E.; Zlotos, D.P. Update on melatonin receptors: Iuphar review 20. *Br. J. Pharmacol.* **2016**, *173*, 2702–2725. [[CrossRef](#)] [[PubMed](#)]
41. Nosjean, O.; Ferro, M.; Coge, F.; Beauverger, P.; Henlin, J.M.; Lefoulon, F.; Fauchere, J.L.; Delagrangé, P.; Canet, E.; Boutin, J.A. Identification of the melatonin-binding site MT3 as the quinone reductase 2. *J. Biol. Chem.* **2000**, *275*, 31311–31317. [[CrossRef](#)] [[PubMed](#)]
42. Boutin, J.A. Quinone reductase 2 as a promising target of melatonin therapeutic actions. *Expert Opin. Ther. Targets* **2016**, *20*, 303–317. [[CrossRef](#)] [[PubMed](#)]
43. Wettschureck, N.; Offermanns, S. Mammalian G proteins and their cell type specific functions. *Physiol. Rev.* **2005**, *85*, 1159–1204. [[CrossRef](#)] [[PubMed](#)]
44. Strathmann, M.; Wilkie, T.M.; Simon, M.I. Diversity of the G-protein family: Sequences from five additional α subunits in the mouse. *Proc. Natl. Acad. Sci. USA* **1989**, *86*, 7407–7409. [[CrossRef](#)] [[PubMed](#)]

45. Birnbaumer, L. Receptor-to-effector signaling through g proteins: Roles for $\beta\gamma$ dimers as well as α subunits. *Cell* **1992**, *71*, 1069–1072. [[CrossRef](#)]
46. Reppert, S.M.; Weaver, D.R.; Godson, C. Melatonin receptors step into the light: Cloning and classification of subtypes. *Trends Pharmacol. Sci.* **1996**, *17*, 100–102. [[CrossRef](#)]
47. Masana, M.I.; Dubocovich, M.L. Melatonin receptor signaling: Finding the path through the dark. *Sci. STKE* **2001**, *2001*, pe39. [[CrossRef](#)] [[PubMed](#)]
48. Brydon, L.; Roka, F.; Petit, L.; de Coppet, P.; Tissot, M.; Barrett, P.; Morgan, P.J.; Nanoff, C.; Strosberg, A.D.; Jockers, R. Dual signaling of human Mel1a melatonin receptors via G(i2), G(i3), and G(q/11) proteins. *Mol. Endocrinol.* **1999**, *13*, 2025–2038. [[CrossRef](#)] [[PubMed](#)]
49. Brydon, L.; Petit, L.; de Coppet, P.; Barrett, P.; Morgan, P.J.; Strosberg, A.D.; Jockers, R. Polymorphism and signalling of melatonin receptors. *Reprod. Nutr. Dev.* **1999**, *39*, 315–324. [[CrossRef](#)] [[PubMed](#)]
50. Jarzynka, M.J.; Passey, D.K.; Ignatius, P.F.; Melan, M.A.; Radio, N.M.; Jockers, R.; Rasenick, M.M.; Brydon, L.; Witt-Enderby, P.A. Modulation of melatonin receptors and G-protein function by microtubules. *J. Pineal Res.* **2006**, *41*, 324–336. [[CrossRef](#)] [[PubMed](#)]
51. Lai, L.; Yuan, L.; Chen, Q.; Dong, C.; Mao, L.; Rowan, B.; Frasch, T.; Hill, S.M. The G α and G α_q proteins mediate the effects of melatonin on steroid/thyroid hormone receptor transcriptional activity and breast cancer cell proliferation. *J. Pineal Res.* **2008**, *45*, 476–488. [[CrossRef](#)] [[PubMed](#)]
52. New, D.C.; Tsim, S.T.; Wong, Y.H. G protein-linked effector and second messenger systems involved in melatonin signal transduction. *Neurosignals* **2003**, *12*, 59–70. [[CrossRef](#)] [[PubMed](#)]
53. Shiu, S.Y.W.; Pang, B.; Tam, C.W.; Yao, K.M. Signal transduction of receptor-mediated antiproliferative action of melatonin on human prostate epithelial cells involves dual activation of G α (s) and G α (q) proteins. *J. Pineal Res.* **2010**, *49*, 301–311. [[CrossRef](#)] [[PubMed](#)]
54. Tam, C.W.; Shiu, S.Y.W. Functional interplay between melatonin receptor-mediated antiproliferative signaling and androgen receptor signaling in human prostate epithelial cells: Potential implications for therapeutic strategies against prostate cancer. *J. Pineal Res.* **2011**, *51*, 297–312. [[CrossRef](#)] [[PubMed](#)]
55. Shiu, S.Y.; Leung, W.Y.; Tam, C.W.; Liu, V.W.; Yao, K.M. Melatonin MT1 receptor-induced transcriptional up-regulation of p27(KIP1) in prostate cancer antiproliferation is mediated via inhibition of constitutively active nuclear factor κ B (NF- κ B): Potential implications on prostate cancer chemoprevention and therapy. *J. Pineal Res.* **2013**, *54*, 69–79. [[PubMed](#)]
56. Hardeland, R. Melatonin: Signaling mechanisms of a pleiotropic agent. *Biofactors* **2009**, *35*, 183–192. [[CrossRef](#)] [[PubMed](#)]
57. Ho, M.K.; Yung, L.Y.; Chan, J.S.; Chan, J.H.; Wong, C.S.; Wong, Y.H. G α (14) links a variety of G(i)- and G(s)-coupled receptors to the stimulation of phospholipase c. *Br. J. Pharmacol.* **2001**, *132*, 1431–1440. [[CrossRef](#)] [[PubMed](#)]
58. McNulty, S.; Ross, A.W.; Barrett, P.; Hastings, M.H.; Morgan, P.J. Melatonin regulates the phosphorylation of CREB in ovine pars tuberalis. *J. Neuroendocrinol.* **1994**, *6*, 523–532. [[CrossRef](#)] [[PubMed](#)]
59. Niles, L.P.; Hashemi, F. Picomolar-affinity binding and inhibition of adenylate cyclase activity by melatonin in syrian hamster hypothalamus. *Cell. Mol. Neurobiol.* **1990**, *10*, 553–558. [[CrossRef](#)] [[PubMed](#)]
60. Morgan, P.J.; Barrett, P.; Howell, H.E.; Helliwell, R. Melatonin receptors: Localization, molecular pharmacology and physiological significance. *Neurochem. Int.* **1994**, *24*, 101–146. [[CrossRef](#)]
61. Witt-Enderby, P.A.; MacKenzie, R.S.; McKeon, R.M.; Carroll, E.A.; Bordt, S.L.; Melan, M.A. Melatonin induction of filamentous structures in non-neuronal cells that is dependent on expression of the human mt1 melatonin receptor. *Cell Motil. Cytoskelet.* **2000**, *46*, 28–42. [[CrossRef](#)]
62. Godson, C.; Reppert, S.M. The Mel1a melatonin receptor is coupled to parallel signal transduction pathways 1. *Endocrinology* **1997**, *138*, 397–404. [[CrossRef](#)] [[PubMed](#)]
63. Roka, F.; Brydon, L.; Waldhoer, M.; Strosberg, A.D.; Freissmuth, M.; Jockers, R.; Nanoff, C. Tight association of the human Mel(1a)-melatonin receptor and G(i): Precoupling and constitutive activity. *Mol. Pharmacol.* **1999**, *56*, 1014–1024. [[PubMed](#)]
64. Wan, Q.; Man, H.Y.; Liu, F.; Brauton, J.; Niznik, H.B.; Pang, S.F.; Brown, G.M.; Wang, Y.T. Differential modulation of GABAA receptor function by Mel1a and Mel1b receptors. *Nat. Neurosci.* **1999**, *2*, 401–403. [[PubMed](#)]

65. Liu, V.W.S.; Yau, W.L.; Tam, C.W.; Yao, K.M.; Shiu, S.Y.W. Melatonin inhibits androgen receptor splice variant-7 (ar-v7)-induced nuclear factor-kappa b (nf-kappab) activation and nf-kappab activator-induced ar-v7 expression in prostate cancer cells: Potential implications for the use of melatonin in castration-resistant prostate cancer (crpc) therapy. *Int. J. Mol. Sci.* **2017**, *18*. [[CrossRef](#)]
66. Tam, C.W.; Mo, C.W.; Yao, K.M.; Shiu, S.Y.W. Signaling mechanisms of melatonin in antiproliferation of hormone-refractory 22RV1 human prostate cancer cells: Implications for prostate cancer chemoprevention. *J. Pineal Res.* **2007**, *42*, 191–202. [[CrossRef](#)] [[PubMed](#)]
67. Tam, C.W.; Chan, K.W.; Liu, V.W.S.; Pang, B.; Yao, K.M.; Shiu, S.Y.W. Melatonin as a negative mitogenic hormonal regulator of human prostate epithelial cell growth: Potential mechanisms and clinical significance. *J. Pineal Res.* **2008**, *45*, 403–412. [[CrossRef](#)] [[PubMed](#)]
68. Chan, A.S.; Lai, F.P.; Lo, R.K.; Voyno-Yasenetskaya, T.A.; Stanbridge, E.J.; Wong, Y.H. Melatonin MT1 and MT2 receptors stimulate c-jun N-terminal kinase via pertussis toxin-sensitive and -insensitive G proteins. *Cell Signal* **2002**, *14*, 249–257. [[CrossRef](#)]
69. Chen, L.; He, X.; Zhang, Y.; Chen, X.; Lai, X.; Shao, J.; Shi, Y.; Zhou, N. Melatonin receptor type 1 signals to extracellular signal-regulated kinase 1 and 2 via Gi and Gs dually coupled pathways in Hek-293 cells. *Biochemistry* **2014**, *53*, 2827–2839. [[CrossRef](#)] [[PubMed](#)]
70. Becker-Andre, M.; Wiesenberg, I.; Schaeren-Wiemers, N.; Andre, E.; Missbach, M.; Saurat, J.H.; Carlberg, C. Pineal gland hormone melatonin binds and activates an orphan of the nuclear receptor superfamily. *J. Biol. Chem.* **1994**, *269*, 28531–28534. [[CrossRef](#)] [[PubMed](#)]
71. Carlberg, C.; Wiesenberg, I. The orphan receptor family RZR/ROR, melatonin and 5-lipoxygenase: An unexpected relationship. *J. Pineal Res.* **1995**, *18*, 171–178. [[CrossRef](#)] [[PubMed](#)]
72. Wiesenberg, I.; Missbach, M.; Kahlen, J.P.; Schrader, M.; Carlberg, C. Transcriptional activation of the nuclear receptor RZR α by the pineal gland hormone melatonin and identification of CGP 52608 as a synthetic ligand. *Nucleic Acids Res.* **1995**, *23*, 327–333. [[CrossRef](#)] [[PubMed](#)]
73. Wiesenberg, I.; Missbach, M.; Carlberg, C. The potential role of the transcription factor RZR/ROR as a mediator of nuclear melatonin signaling. *Restor. Neurol. Neurosci.* **1998**, *12*, 143–150. [[PubMed](#)]
74. Acuna-Castroviejo, D.; Reiter, R.J.; Menendez-Pelaez, A.; Pablos, M.I.; Burgos, A. Characterization of high-affinity melatonin binding sites in purified cell nuclei of rat liver. *J. Pineal Res.* **1994**, *16*, 100–112. [[CrossRef](#)] [[PubMed](#)]
75. Zhang, Y.; Luo, X.Y.; Wu, D.H.; Xu, Y. ROR nuclear receptors: Structures, related diseases, and drug discovery. *Acta Pharmacol. Sin.* **2015**, *36*, 71–87. [[CrossRef](#)] [[PubMed](#)]
76. Giguere, V.; McBroom, L.D.; Flock, G. Determinants of target gene specificity for ROR α 1: Monomeric DNA binding by an orphan nuclear receptor. *Mol. Cell. Biol.* **1995**, *15*, 2517–2526. [[CrossRef](#)] [[PubMed](#)]
77. Giguere, V.; Tini, M.; Flock, G.; Ong, E.; Evans, R.M.; Otulakowski, G. Isoform-specific amino-terminal domains dictate DNA-binding properties of ROR α , a novel family of orphan hormone nuclear receptors. *Genes Dev.* **1994**, *8*, 538–553. [[CrossRef](#)] [[PubMed](#)]
78. Medvedev, A.; Yan, Z.H.; Hirose, T.; Giguere, V.; Jetten, A.M. Cloning of a cDNA encoding the murine orphan receptor RZR/ROR γ and characterization of its response element. *Gene* **1996**, *181*, 199–206. [[CrossRef](#)]
79. Schrader, M.; Danielsson, C.; Wiesenberg, I.; Carlberg, C. Identification of natural monomeric response elements of the nuclear receptor RZR/ROR. They also bind coup-TF homodimers. *J. Biol. Chem.* **1996**, *271*, 19732–19736. [[CrossRef](#)] [[PubMed](#)]
80. Winrow, C.J.; Capone, J.P.; Rachubinski, R.A. Cross-talk between orphan nuclear hormone receptor RZR α and peroxisome proliferator-activated receptor α in regulation of the peroxisomal hydratase-dehydrogenase gene. *J. Biol. Chem.* **1998**, *273*, 31442–31448. [[CrossRef](#)] [[PubMed](#)]
81. Karasek, M.; Carrillo-Vico, A.; Guerrero, J.M.; Winczyk, K.; Pawlikowski, M. Expression of melatonin MT(1) and MT(2) receptors, and ROR α (1) receptor in transplantable murine colon 38 cancer. *Neuro Endocrinol. Lett.* **2002**, *23* (Suppl. 1), 55–60. [[PubMed](#)]
82. Winczyk, K.; Pawlikowski, M.; Guerrero, J.M.; Karasek, M. Possible involvement of the nuclear RZR/ROR- α receptor in the antitumor action of melatonin on murine colon 38 cancer. *Tumour Biol.* **2002**, *23*, 298–302. [[CrossRef](#)] [[PubMed](#)]
83. Garcia-Maurino, S.; Pozo, D.; Calvo, J.R.; Guerrero, J.M. Correlation between nuclear melatonin receptor expression and enhanced cytokine production in human lymphocytic and monocytic cell lines. *J. Pineal Res.* **2000**, *29*, 129–137. [[CrossRef](#)] [[PubMed](#)]

84. Guerrero, J.M.; Pozo, D.; Garcia-Maurino, S.; Osuna, C.; Molinero, P.; Calvo, J.R. Involvement of nuclear receptors in the enhanced IL-2 production by melatonin in jurkat cells. *Ann. N. Y. Acad. Sci.* **2000**, *917*, 397–403. [[CrossRef](#)] [[PubMed](#)]
85. Guerrero, J.M.; Pozo, D.; Garcia-Maurino, S.; Carrillo, A.; Osuna, C.; Molinero, P.; Calvo, J.R. Nuclear receptors are involved in the enhanced IL-6 production by melatonin in u937 cells. *Biol. Signals Recept.* **2000**, *9*, 197–202. [[CrossRef](#)] [[PubMed](#)]
86. Tang, X.H.; Gudas, L.J. Retinoids, retinoic acid receptors, and cancer. *Annu. Rev. Pathol.* **2011**, *6*, 345–364. [[CrossRef](#)] [[PubMed](#)]
87. Steinhilber, D.; Brungs, M.; Werz, O.; Wiesenberger, I.; Danielsson, C.; Kahlen, J.P.; Nayeri, S.; Schrader, M.; Carlberg, C. The nuclear receptor for melatonin represses 5-lipoxygenase gene expression in human b lymphocytes. *J. Biol. Chem.* **1995**, *270*, 7037–7040. [[CrossRef](#)] [[PubMed](#)]
88. Dai, J.; Ram, P.T.; Yuan, L.; Spriggs, L.L.; Hill, S.M. Transcriptional repression of ROR α activity in human breast cancer cells by melatonin. *Mol. Cell. Endocrinol.* **2001**, *176*, 111–120. [[CrossRef](#)]
89. Dong, C.; Yuan, L.; Dai, J.; Lai, L.; Mao, L.; Xiang, S.; Rowan, B.; Hill, S.M. Melatonin inhibits mitogenic cross-talk between retinoic acid-related orphan receptor α (ROR α) and ER α in MCF-7 human breast cancer cells. *Steroids* **2010**, *75*, 944–951. [[CrossRef](#)] [[PubMed](#)]
90. Wang, R.X.; Liu, H.; Xu, L.; Zhang, H.; Zhou, R.X. Melatonin downregulates nuclear receptor RZR/ROR γ expression causing growth-inhibitory and anti-angiogenesis activity in human gastric cancer cells in vitro and in vivo. *Oncol. Lett.* **2016**, *12*, 897–903. [[CrossRef](#)] [[PubMed](#)]
91. Reiter, R.J.; Rosales-Corral, S.A.; Tan, D.X.; Acuna-Castroviejo, D.; Qin, L.; Yang, S.F.; Xu, K. Melatonin, a full service anti-cancer agent: Inhibition of initiation, progression and metastasis. *Int. J. Mol. Sci.* **2017**, *18*, E843. [[CrossRef](#)] [[PubMed](#)]
92. Chuffa, L.G.A.; Reiter, R.J.; Lupi Junior, L.A. Melatonin as a promising agent to treat ovarian cancer: Molecular mechanisms. *Carcinogenesis* **2017**. [[CrossRef](#)] [[PubMed](#)]
93. Li, W.; Fan, M.; Chen, Y.; Zhao, Q.; Song, C.; Yan, Y.; Jin, Y.; Huang, Z.; Lin, C.; Wu, J. Melatonin induces cell apoptosis in ags cells through the activation of jnk and p38 mapk and the suppression of nuclear factor- κ B: A novel therapeutic implication for gastric cancer. *Cell. Physiol. Biochem.* **2015**, *37*, 2323–2338. [[CrossRef](#)] [[PubMed](#)]
94. Kim, C.H.; Yoo, Y.M. Melatonin induces apoptotic cell death via p53 in Incap cells. *Korean J. Physiol. Pharmacol.* **2010**, *14*, 365–369. [[CrossRef](#)] [[PubMed](#)]
95. Li, W.; Wu, J.; Li, Z.; Zhou, Z.; Zheng, C.; Lin, L.; Tan, B.; Huang, M.; Fan, M. Melatonin induces cell apoptosis in mia PACA-2 cells via the suppression of nuclear factor- κ B and activation of ERK and JNK: A novel therapeutic implication for pancreatic cancer. *Oncol. Rep.* **2016**, *36*, 2861–2867. [[CrossRef](#)] [[PubMed](#)]
96. Cabrera, J.; Negrin, G.; Estevez, F.; Loro, J.; Reiter, R.J.; Quintana, J. Melatonin decreases cell proliferation and induces melanogenesis in human melanoma SK-Mel-1 cells. *J. Pineal Res.* **2010**, *49*, 45–54. [[CrossRef](#)] [[PubMed](#)]
97. Carbajo-Pescador, S.; Garcia-Palomo, A.; Martin-Renedo, J.; Piva, M.; Gonzalez-Gallego, J.; Mauriz, J.L. Melatonin modulation of intracellular signaling pathways in hepatocarcinoma HEPG2 cell line: Role of the MT1 receptor. *J. Pineal Res.* **2011**, *51*, 463–471. [[CrossRef](#)] [[PubMed](#)]
98. Santoro, R.; Marani, M.; Blandino, G.; Muti, P.; Strano, S. Melatonin triggers p53Ser phosphorylation and prevents DNA damage accumulation. *Oncogene* **2012**, *31*, 2931–2942. [[CrossRef](#)] [[PubMed](#)]
99. Santoro, R.; Mori, F.; Marani, M.; Grasso, G.; Cambria, M.A.; Blandino, G.; Muti, P.; Strano, S. Blockage of melatonin receptors impairs p53-mediated prevention of DNA damage accumulation. *Carcinogenesis* **2013**, *34*, 1051–1061. [[CrossRef](#)] [[PubMed](#)]
100. Mori, F.; Ferraiuolo, M.; Santoro, R.; Sacconi, A.; Goeman, F.; Pallocca, M.; Pulito, C.; Korita, E.; Fanciulli, M.; Muti, P.; et al. Multitargeting activity of MIR-24 inhibits long-term melatonin anticancer effects. *Oncotarget* **2016**, *7*, 20532–20548. [[CrossRef](#)] [[PubMed](#)]
101. Gao, Y.; Xiao, X.; Zhang, C.; Yu, W.; Guo, W.; Zhang, Z.; Li, Z.; Feng, X.; Hao, J.; Zhang, K.; et al. Melatonin synergizes the chemotherapeutic effect of 5-fluorouracil in colon cancer by suppressing pi3k/AKT and Nf- κ B/INOS signaling pathways. *J. Pineal Res.* **2017**, *62*. [[CrossRef](#)] [[PubMed](#)]
102. Lu, J.J.; Fu, L.; Tang, Z.; Zhang, C.; Qin, L.; Wang, J.; Yu, Z.; Shi, D.; Xiao, X.; Xie, F.; et al. Melatonin inhibits AP-2 β /HTERT, NF- κ B/Cox-2 and AKT/ERK and activates caspase/cyto c signaling to enhance the antitumor activity of berberine in lung cancer cells. *Oncotarget* **2016**, *7*, 2985–3001. [[CrossRef](#)] [[PubMed](#)]

103. Ju, H.Q.; Li, H.; Tian, T.; Lu, Y.X.; Bai, L.; Chen, L.Z.; Sheng, H.; Mo, H.Y.; Zeng, J.B.; Deng, W.; et al. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor- κ B activation. *J. Pineal Res.* **2016**, *60*, 27–38. [[CrossRef](#)] [[PubMed](#)]
104. Lin, Y.W.; Lee, L.M.; Lee, W.J.; Chu, C.Y.; Tan, P.; Yang, Y.C.; Chen, W.Y.; Yang, S.F.; Hsiao, M.; Chien, M.H. Melatonin inhibits MMP-9 transactivation and renal cell carcinoma metastasis by suppressing AKT-MAPKS pathway and NF- κ B DNA-binding activity. *J. Pineal Res.* **2016**, *60*, 277–290. [[CrossRef](#)] [[PubMed](#)]
105. Chen, X.; Hao, A.; Li, X.; Du, Z.; Li, H.; Wang, H.; Yang, H.; Fang, Z. Melatonin inhibits tumorigenicity of glioblastoma stem-like cells via the AKT-EZH2-STAT3 signaling axis. *J. Pineal Res.* **2016**, *61*, 208–217. [[CrossRef](#)] [[PubMed](#)]
106. Zheng, X.; Pang, B.; Gu, G.; Gao, T.; Zhang, R.; Pang, Q.; Liu, Q. Melatonin inhibits glioblastoma stem-like cells through suppression of EZH2-notch1 signaling axis. *Int. J. Biol. Sci.* **2017**, *13*, 245–253. [[CrossRef](#)] [[PubMed](#)]
107. Liu, L.; Xu, Y.; Reiter, R.J.; Pan, Y.; Chen, D.; Liu, Y.; Pu, X.; Jiang, L.; Li, Z. Inhibition of ERK1/2 signaling pathway is involved in melatonin's antiproliferative effect on human MG-63 osteosarcoma cells. *Cell. Physiol. Biochem.* **2016**, *39*, 2297–2307. [[CrossRef](#)] [[PubMed](#)]
108. Konakchieva, R.; Todorov, P. Melatonin protects human spermatozoa from apoptosis via melatonin receptor- and extracellular signal-regulated kinase-mediated pathways. *Fertil. Steril.* **2011**, *96*, e159. [[CrossRef](#)] [[PubMed](#)]
109. Molpeceres, V.; Mauriz, J.L.; Garcia-Mediavilla, M.V.; Gonzalez, P.; Barrio, J.P.; Gonzalez-Gallego, J. Melatonin is able to reduce the apoptotic liver changes induced by aging via inhibition of the intrinsic pathway of apoptosis. *J. Gerontol. A Biol. Sci. Med. Sci.* **2007**, *62*, 687–695. [[CrossRef](#)] [[PubMed](#)]
110. Wang, X. The antiapoptotic activity of melatonin in neurodegenerative diseases. *CNS Neurosci. Ther.* **2009**, *15*, 345–357. [[CrossRef](#)] [[PubMed](#)]
111. Ren, W.; Liu, G.; Chen, S.; Yin, J.; Wang, J.; Tan, B.; Wu, G.; Bazer, F.W.; Peng, Y.; Li, T.; et al. Melatonin signaling in T cells: Functions and applications. *J. Pineal Res.* **2017**, *62*. [[CrossRef](#)] [[PubMed](#)]
112. GarciaMaurino, S.; GonzalezHaba, M.G.; Calvo, J.R.; RafiiElIdrissi, M.; SanchezMargalet, V.; Goberna, R.; Guerrero, J.M. Melatonin enhances IL-2, IL-6, and IFN- γ production by human circulating CD4(+) cells—A possible nuclear receptor-mediated mechanism involving T helper type 1 lymphocytes and monocytes. *J. Immunol.* **1997**, *159*, 574–581.
113. Lardone, P.J.; Carrillo-Vico, A.; Naranjo, M.C.; de Felipe, B.; Vallejo, A.; Karasek, M.; Guerrero, J.M. Melatonin synthesized by jurkat human leukemic T cell line is implicated in IL-2 production. *J. Cell. Physiol.* **2006**, *206*, 273–279. [[CrossRef](#)] [[PubMed](#)]
114. Ha, E.; Han, E.; Park, H.J.; Kim, H.J.; Hong, M.S.; Hong, S.J.; Yoon, K.S.; Kang, I.; Cho, Y.H.; Chung, J.H.; et al. Microarray analysis of transcription factor gene expression in melatonin-treated human peripheral blood mononuclear cells. *J. Pineal Res.* **2006**, *40*, 305–311. [[CrossRef](#)] [[PubMed](#)]
115. Calvo, J.R.; Gonzalez-Yanes, C.; Maldonado, M.D. The role of melatonin in the cells of the innate immunity: A review. *J. Pineal Res.* **2013**, *55*, 103–120. [[CrossRef](#)] [[PubMed](#)]
116. Lardone, P.J.; Carrillo-Vico, A.; Molinero, P.; Rubio, A.; Guerrero, J.M. A novel interplay between membrane and nuclear melatonin receptors in human lymphocytes: Significance in IL-2 production. *Cell. Mol. Life Sci.* **2009**, *66*, 516–525. [[CrossRef](#)] [[PubMed](#)]
117. Carrillo-Vico, A.; Lardone, P.J.; Alvarez-Sanchez, N.; Rodriguez-Rodriguez, A.; Guerrero, J.M. Melatonin: Buffering the immune system. *Int. J. Mol. Sci.* **2013**, *14*, 8638–8683. [[CrossRef](#)] [[PubMed](#)]
118. Currier, N.L.; Sun, L.Z.Y.; Miller, S.C. Exogenous melatonin: Quantitative enhancement in vivo of cells mediating non-specific immunity. *J. Neuroimmunol.* **2000**, *104*, 101–108. [[CrossRef](#)]
119. Vigore, L.; Messina, G.; Brivio, F.; Fumagalli, L.; Rovelli, F.; G, D.I.F.; Lissoni, P. Psychoneuroendocrine modulation of regulatory T lymphocyte system: In vivo and in vitro effects of the pineal immunomodulating hormone melatonin. *In Vivo* **2010**, *24*, 787–789. [[PubMed](#)]
120. Liu, H.; Xu, L.; Wei, J.E.; Xie, M.R.; Wang, S.E.; Zhou, R.X. Role of CD4+ CD25+ regulatory T cells in melatonin-mediated inhibition of murine gastric cancer cell growth in vivo and in vitro. *Anat. Rec.* **2011**, *294*, 781–788. [[CrossRef](#)] [[PubMed](#)]
121. Knutson, K.L.; Disis, M.L.; Salazar, L.G. CD4 regulatory T cells in human cancer pathogenesis. *Cancer Immunol. Immunother.* **2007**, *56*, 271–285. [[CrossRef](#)] [[PubMed](#)]

122. Cos, S.; Fernandez, R.; Guezmes, A.; Sanchez-Barcelo, E.J. Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. *Cancer Res.* **1998**, *58*, 4383–4390. [[PubMed](#)]
123. Wu, S.M.; Lin, W.Y.; Shen, C.C.; Pan, H.C.; Keh-Bin, W.; Chen, Y.C.; Jan, Y.J.; Lai, D.W.; Tang, S.C.; Tien, H.R.; et al. Melatonin set out to ER stress signaling thwarts epithelial mesenchymal transition and peritoneal dissemination via calpain-mediated c/EBP β and NF κ B cleavage. *J. Pineal Res.* **2016**, *60*, 142–154. [[CrossRef](#)] [[PubMed](#)]
124. Goncalves Ndo, N.; Colombo, J.; Lopes, J.R.; Gelaleti, G.B.; Moschetta, M.G.; Sonehara, N.M.; Hellmen, E.; Zanon Cde, F.; Oliani, S.M.; Zuccari, D.A. Effect of melatonin in epithelial mesenchymal transition markers and invasive properties of breast cancer stem cells of canine and human cell lines. *PLoS ONE* **2016**, *11*, e0150407.
125. Zhou, Q.; Gui, S.; Zhou, Q.; Wang, Y. Melatonin inhibits the migration of human lung adenocarcinoma a549 cell lines involving JNK/MAPK pathway. *PLoS ONE* **2014**, *9*, e101132. [[CrossRef](#)] [[PubMed](#)]
126. Borin, T.F.; Arbab, A.S.; Gelaleti, G.B.; Ferreira, L.C.; Moschetta, M.G.; Jardim-Perassi, B.V.; Iskander, A.S.; Varma, N.R.; Shankar, A.; Coimbra, V.B.; et al. Melatonin decreases breast cancer metastasis by modulating rho-associated kinase protein-1 expression. *J. Pineal Res.* **2016**, *60*, 3–15. [[CrossRef](#)] [[PubMed](#)]
127. Goncalves Ndo, N.; Rodrigues, R.V.; Jardim-Perassi, B.V.; Moschetta, M.G.; Lopes, J.R.; Colombo, J.; Zuccari, D.A. Molecular markers of angiogenesis and metastasis in lines of oral carcinoma after treatment with melatonin. *Anticancer Agents Med. Chem.* **2014**, *14*, 1302–1311. [[CrossRef](#)] [[PubMed](#)]
128. Lopes, J.; Arnosti, D.; Trosko, J.E.; Tai, M.H.; Zuccari, D. Melatonin decreases estrogen receptor binding to estrogen response elements sites on the OCT4 gene in human breast cancer stem cells. *Genes Cancer* **2016**, *7*, 209–217. [[PubMed](#)]
129. Lopes, J.R.; da Silva Kavagutti, M.; Medeiros, F.A.; De Campos Zuccari, D.A. Evaluation of melatonin effect on human breast cancer stem cells using a three-dimensional growth method of mammospheres. *Anticancer Agents Med. Chem.* **2016**. [[CrossRef](#)]
130. Nooshinfar, E.; Bashash, D.; Safaroghli-Azar, A.; Bayati, S.; Rezaei-Tavirani, M.; Ghaffari, S.H.; Akbari, M.E. Melatonin promotes ATO-induced apoptosis in MCF-7 cells: Proposing novel therapeutic potential for breast cancer. *Biomed. Pharmacother.* **2016**, *83*, 456–465. [[CrossRef](#)] [[PubMed](#)]
131. Lu, Y.X.; Chen, D.L.; Wang, D.S.; Chen, L.Z.; Mo, H.Y.; Sheng, H.; Bai, L.; Wu, Q.N.; Yu, H.E.; Xie, D.; et al. Melatonin enhances sensitivity to fluorouracil in oesophageal squamous cell carcinoma through inhibition of ERK and AKT pathway. *Cell Death Dis.* **2016**, *7*, e2432. [[CrossRef](#)] [[PubMed](#)]
132. Zhelev, Z.; Ivanova, D.; Bakalova, R.; Aoki, I.; Higashi, T. Synergistic cytotoxicity of melatonin and new-generation anticancer drugs against leukemia lymphocytes but not normal lymphocytes. *Anticancer Res.* **2017**, *37*, 149–159. [[CrossRef](#)] [[PubMed](#)]
133. Wang, Y.P.; Yang, Z.P. Effects of melatonin combined with cis-platinum or methotrexate on the proliferation of osteosarcoma cell line SAOS-2. *Zhongguo Yi Xue Ke Xue Yuan Xue Bao* **2015**, *37*, 215–220. [[PubMed](#)]
134. Fan, L.; Sun, G.; Ma, T.; Zhong, F.; Lei, Y.; Li, X.; Wei, W. Melatonin reverses tunicamycin-induced endoplasmic reticulum stress in human hepatocellular carcinoma cells and improves cytotoxic response to doxorubicin by increasing chop and decreasing survivin. *J. Pineal Res.* **2013**, *55*, 184–194. [[CrossRef](#)] [[PubMed](#)]
135. Maschio-Signorini, L.B.; Gelaleti, G.B.; Moschetta, M.G.; Borin, T.F.; Jardim-Perassi, B.V.; Lopes, J.R.; Lacerda, J.Z.; Roela, R.A.; Bordin, N.A.; Correa, L.A.; et al. Melatonin regulates angiogenic and inflammatory proteins in MDA-MB-231 cell line and in co-culture with cancer-associated fibroblasts. *Anticancer Agents Med. Chem.* **2016**, *16*, 1474–1484. [[CrossRef](#)] [[PubMed](#)]
136. Park, S.Y.; Jang, W.J.; Yi, E.Y.; Jang, J.Y.; Jung, Y.; Jeong, J.W.; Kim, Y.J. Melatonin suppresses tumor angiogenesis by inhibiting Hif-1 α stabilization under hypoxia. *J. Pineal Res.* **2010**, *48*, 178–184. [[CrossRef](#)] [[PubMed](#)]
137. Cui, P.; Yu, M.; Peng, X.; Dong, L.; Yang, Z. Melatonin prevents human pancreatic carcinoma cell PANC-1-induced human umbilical vein endothelial cell proliferation and migration by inhibiting vascular endothelial growth factor expression. *J. Pineal Res.* **2012**, *52*, 236–243. [[CrossRef](#)] [[PubMed](#)]
138. Dai, M.; Cui, P.; Yu, M.; Han, J.; Li, H.; Xiu, R. Melatonin modulates the expression of VEGF and Hif-1 α induced by COCL2 in cultured cancer cells. *J. Pineal Res.* **2008**, *44*, 121–126. [[CrossRef](#)] [[PubMed](#)]
139. Lv, D.; Cui, P.L.; Yao, S.W.; Xu, Y.Q.; Yang, Z.X. Melatonin inhibits the expression of vascular endothelial growth factor in pancreatic cancer cells. *Chin. J. Cancer Res.* **2012**, *24*, 310–316. [[CrossRef](#)] [[PubMed](#)]

140. Gonzalez, A.; Gonzalez-Gonzalez, A.; Alonso-Gonzalez, C.; Menendez-Menendez, J.; Martinez-Campa, C.; Cos, S. Melatonin inhibits angiogenesis in SH-SY5Y human neuroblastoma cells by downregulation of VEGF. *Oncol. Rep.* **2017**, *37*, 2433–2440. [[CrossRef](#)] [[PubMed](#)]
141. Carbajo-Pescador, S.; Ordonez, R.; Benet, M.; Jover, R.; Garcia-Palomo, A.; Mauriz, J.L.; Gonzalez-Gallego, J. Inhibition of VEGF expression through blockade of Hif1 α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HEPG2 liver cancer cells. *Br. J. Cancer* **2013**, *109*, 83–91. [[CrossRef](#)] [[PubMed](#)]
142. Jardim-Perassi, B.V.; Lourenco, M.R.; Doho, G.M.; Grigolo, I.H.; Gelaleti, G.B.; Ferreira, L.C.; Borin, T.F.; Moschetta, M.G.; Pires de Campos Zuccari, D.A. Melatonin regulates angiogenic factors under hypoxia in breast cancer cell lines. *Anticancer Agents Med. Chem.* **2016**, *16*, 347–358. [[CrossRef](#)] [[PubMed](#)]
143. Jardim-Perassi, B.V.; Arbab, A.S.; Ferreira, L.C.; Borin, T.F.; Varma, N.R.; Iskander, A.S.; Shankar, A.; Ali, M.M.; Pires de Campos Zuccari, D.A. Effect of melatonin on tumor growth and angiogenesis in xenograft model of breast cancer. *PLoS ONE* **2014**, *9*, e85311. [[CrossRef](#)] [[PubMed](#)]
144. Alvarez-Garcia, V.; Gonzalez, A.; Alonso-Gonzalez, C.; Martinez-Campa, C.; Cos, S. Antiangiogenic effects of melatonin in endothelial cell cultures. *Microvasc. Res.* **2013**, *87*, 25–33. [[CrossRef](#)] [[PubMed](#)]
145. Akbarzadeh, M.; Rahbarghazi, R.; Nabat, E.; Movassaghpour, A.A.; Shanehbandi, D.; Faramarzian Azimi Maragheh, B.; Matluobi, D.; Barazvan, B.; Kazemi, M.; Samadi, N.; et al. The impact of different extracellular matrices on melatonin effect in proliferation and stemness properties of ovarian cancer cells. *Biomed. Pharmacother.* **2017**, *87*, 288–295. [[CrossRef](#)] [[PubMed](#)]
146. Colombo, J.; Maciel, J.M.; Ferreira, L.C.; Silva, R.F.D.; Zuccari, D.A. Effects of melatonin on Hif-1 α and vegf expression and on the invasive properties of hepatocarcinoma cells. *Oncol. Lett.* **2016**, *12*, 231–237. [[CrossRef](#)] [[PubMed](#)]
147. Rimler, A.; Lupowitz, Z.; Zisapel, N. Differential regulation by melatonin of cell growth and androgen receptor binding to the androgen response element in prostate cancer cells. *Neuro Endocrinol. Lett.* **2002**, *23* (Suppl. 1), 45–49. [[PubMed](#)]
148. Rimler, A.; Culig, Z.; Lupowitz, Z.; Zisapel, N. Nuclear exclusion of the androgen receptor by melatonin. *J. Steroid. Biochem. Mol. Biol.* **2002**, *81*, 77–84. [[CrossRef](#)]
149. Rimler, A.; Culig, Z.; Levy-Rimler, G.; Lupowitz, Z.; Klocker, H.; Matzkin, H.; Bartsch, G.; Zisapel, N. Melatonin elicits nuclear exclusion of the human androgen receptor and attenuates its activity. *Prostate* **2001**, *49*, 145–154. [[CrossRef](#)] [[PubMed](#)]
150. Hill, S.M.; Spriggs, L.L.; Simon, M.A.; Muraoka, H.; Blask, D.E. The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system. *Cancer Lett.* **1992**, *64*, 249–256. [[CrossRef](#)]
151. Cos, S.; Sanchez-Barcelo, E.J. Melatonin, experimental basis for a possible application in breast cancer prevention and treatment. *Histol. Histopathol.* **2000**, *15*, 637–647. [[PubMed](#)]
152. Sanchez-Barcelo, E.J.; Cos, S.; Mediavilla, D.; Martinez-Campa, C.; Gonzalez, A.; Alonso-Gonzalez, C. Melatonin-estrogen interactions in breast cancer. *J. Pineal Res.* **2005**, *38*, 217–222. [[CrossRef](#)] [[PubMed](#)]
153. Del Rio, B.; Garcia Pedrero, J.M.; Martinez-Campa, C.; Zuazua, P.; Lazo, P.S.; Ramos, S. Melatonin, an endogenous-specific inhibitor of estrogen receptor α via calmodulin. *J. Biol. Chem.* **2004**, *279*, 38294–38302. [[CrossRef](#)] [[PubMed](#)]
154. Mao, L.; Cheng, Q.; Guardiola-Lemaitre, B.; Schuster-Klein, C.; Dong, C.; Lai, L.; Hill, S.M. In vitro and in vivo antitumor activity of melatonin receptor agonists. *J. Pineal Res.* **2010**, *49*, 210–221. [[CrossRef](#)] [[PubMed](#)]
155. Hill, S.M.; Frasc, T.; Xiang, S.; Yuan, L.; Duplessis, T.; Mao, L. Molecular mechanisms of melatonin anticancer effects. *Integr. Cancer Ther.* **2009**, *8*, 337–346. [[CrossRef](#)] [[PubMed](#)]
156. Oprea-Ilie, G.; Haus, E.; Sackett-Lundeen, L.; Liu, Y.; McLendon, L.; Busch, R.; Adams, A.; Cohen, C. Expression of melatonin receptors in triple negative breast cancer (tnbc) in african american and caucasian women: Relation to survival. *Breast Cancer Res. Treat.* **2013**, *137*, 677–687. [[CrossRef](#)] [[PubMed](#)]
157. Yuan, L.; Collins, A.R.; Dai, J.; Dubocovich, M.L.; Hill, S.M. MT(1) Melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. *Mol. Cell. Endocrinol.* **2002**, *192*, 147–156. [[CrossRef](#)]
158. Collins, A.; Yuan, L.; Kiefer, T.L.; Cheng, Q.; Lai, L.; Hill, S.M. Overexpression of the MT1 melatonin receptor in MCF-7 human breast cancer cells inhibits mammary tumor formation in nude mice. *Cancer Lett.* **2003**, *189*, 49–57. [[CrossRef](#)]

159. Nemeth, C.; Humpeler, S.; Kallay, E.; Mesteri, I.; Svoboda, M.; Rogelsperger, O.; Klammer, N.; Thalhammer, T.; Ekmekcioglu, C. Decreased expression of the melatonin receptor 1 in human colorectal adenocarcinomas. *J. Biol. Regul. Homeost. Agents* **2011**, *25*, 531–542. [[PubMed](#)]
160. Leon, J.; Casado, J.; Carazo, A.; Sanjuan, L.; Mate, A.; Munoz de Rueda, P.; de la Cueva, P.; Quiles, R.; Ruiz, S.; Ruiz-Extremuera, A.; et al. Gender-related invasion differences associated with mRNA expression levels of melatonin membrane receptors in colorectal cancer. *Mol. Carcinog.* **2012**, *51*, 608–618. [[CrossRef](#)] [[PubMed](#)]
161. Kobayashi, Y.; Itoh, M.T.; Kondo, H.; Okuma, Y.; Sato, S.; Kanishi, Y.; Hamada, N.; Kiguchi, K.; Ishizuka, B. Melatonin binding sites in estrogen receptor-positive cells derived from human endometrial cancer. *J. Pineal Res.* **2003**, *35*, 71–74. [[PubMed](#)]
162. Wang, R.X.; Liu, H.; Xu, L.; Zhang, H.; Zhou, R.X. Involvement of nuclear receptor RZR/ROR γ in melatonin-induced Hif-1 α inactivation in SGC-7901 human gastric cancer cells. *Oncol. Rep.* **2015**, *34*, 2541–2546. [[CrossRef](#)] [[PubMed](#)]
163. Winczyk, K.; Pawlikowski, M.; Karasek, M. Melatonin and RZR/ROR receptor ligand CGP 52608 induce apoptosis in the murine colonic cancer. *J. Pineal Res.* **2001**, *31*, 179–182. [[CrossRef](#)] [[PubMed](#)]
164. Petranka, J.; Baldwin, W.; Biermann, J.; Jayadev, S.; Barrett, J.C.; Murphy, E. The oncostatic action of melatonin in an ovarian carcinoma cell line. *J. Pineal Res.* **1999**, *26*, 129–136. [[CrossRef](#)] [[PubMed](#)]
165. Narendhirakannan, R.T.; Hannah, M.A. Oxidative stress and skin cancer: An overview. *Indian J. Clin. Biochem.* **2013**, *28*, 110–115. [[CrossRef](#)] [[PubMed](#)]
166. Sosa, V.; Moline, T.; Somoza, R.; Paciucci, R.; Kondoh, H.; ME, L.L. Oxidative stress and cancer: An overview. *Ageing Res. Rev.* **2013**, *12*, 376–390. [[CrossRef](#)] [[PubMed](#)]
167. Reiter, R.J.; Tan, D.X.; Mayo, J.C.; Sainz, R.M.; Leon, J.; Czarnocki, Z. Melatonin as an antioxidant: Biochemical mechanisms and pathophysiological implications in humans. *Acta Biochim. Pol.* **2003**, *50*, 1129–1146. [[PubMed](#)]
168. Rodriguez, C.; Mayo, J.C.; Sainz, R.M.; Antolin, I.; Herrera, F.; Martin, V.; Reiter, R.J. Regulation of antioxidant enzymes: A significant role for melatonin. *J. Pineal Res.* **2004**, *36*, 1–9. [[CrossRef](#)] [[PubMed](#)]
169. Ramis, M.R.; Esteban, S.; Miralles, A.; Tan, D.X.; Reiter, R.J. Protective effects of melatonin and mitochondria-targeted antioxidants against oxidative stress: A review. *Curr. Med. Chem.* **2015**, *22*, 2690–2711. [[CrossRef](#)] [[PubMed](#)]
170. Tan, D.X.; Manchester, L.C.; Qin, L.; Reiter, R.J. Melatonin: A mitochondrial targeting molecule involving mitochondrial protection and dynamics. *Int. J. Mol. Sci.* **2016**, *17*. [[CrossRef](#)] [[PubMed](#)]
171. Proietti, S.; Cucina, A.; Minini, M.; Bizzarri, M. Melatonin, mitochondria, and the cancer cell. *Cell. Mol. Life Sci.* **2017**. [[CrossRef](#)] [[PubMed](#)]
172. Opie, L.H.; Lecour, S. Melatonin has multiorgan effects. *Eur. Heart J. Cardiovasc. Pharmacother.* **2016**, *2*, 258–265. [[CrossRef](#)] [[PubMed](#)]
173. Cardinali, D.P.; Hardeland, R. Inflammaging, metabolic syndrome and melatonin: A call for treatment studies. *Neuroendocrinology* **2017**, *104*, 382–397. [[CrossRef](#)] [[PubMed](#)]
174. Sun, H.; Gusdon, A.M.; Qu, S. Effects of melatonin on cardiovascular diseases: Progress in the past year. *Curr. Opin. Lipidol.* **2016**, *27*, 408–413. [[CrossRef](#)] [[PubMed](#)]
175. Quera Salva, M.A.; Hartley, S. Mood disorders, circadian rhythms, melatonin and melatonin agonists. *J. Cent. Nerv. Syst. Dis.* **2012**, *4*, 15–26. [[CrossRef](#)] [[PubMed](#)]
176. Zhang, J.J.; Meng, X.; Li, Y.; Zhou, Y.; Xu, D.P.; Li, S.; Li, H.B. Effects of melatonin on liver injuries and diseases. *Int. J. Mol. Sci.* **2017**, *18*. [[CrossRef](#)] [[PubMed](#)]
177. Hahn, R.A. Profound bilateral blindness and the incidence of breast cancer. *Epidemiology* **1991**, *2*, 208–210. [[CrossRef](#)] [[PubMed](#)]
178. Klerman, E.B.; Zeitzer, J.M.; Duffy, J.F.; Khalsa, S.B.; Czeisler, C.A. Absence of an increase in the duration of the circadian melatonin secretory episode in totally blind human subjects. *J. Clin. Endocrinol. Metab.* **2001**, *86*, 3166–3170. [[CrossRef](#)] [[PubMed](#)]
179. Alpert, M.; Carome, E.; Kubulins, V.; Hansler, R. Nighttime use of special spectacles or light bulbs that block blue light may reduce the risk of cancer. *Med. Hypotheses* **2009**, *73*, 324–325. [[CrossRef](#)] [[PubMed](#)]
180. Flynn-Evans, E.E.; Stevens, R.G.; Tabandeh, H.; Schernhammer, E.S.; Lockley, S.W. Total visual blindness is protective against breast cancer. *Cancer Causes Control* **2009**, *20*, 1753–1756. [[CrossRef](#)] [[PubMed](#)]
181. Kliukiene, J.; Tynes, T.; Andersen, A. Risk of breast cancer among norwegian women with visual impairment. *Br. J. Cancer* **2001**, *84*, 397–399. [[CrossRef](#)] [[PubMed](#)]

182. Blakeman, V.; Williams, J.L.; Meng, Q.J.; Streuli, C.H. Circadian clocks and breast cancer. *Breast Cancer Res.* **2016**, *18*, 89. [[CrossRef](#)] [[PubMed](#)]
183. Stevens, R.G.; Brainard, G.C.; Blask, D.E.; Lockley, S.W.; Motta, M.E. Breast cancer and circadian disruption from electric lighting in the modern world. *CA Cancer J. Clin.* **2014**, *64*, 207–218. [[CrossRef](#)] [[PubMed](#)]
184. He, C.; Anand, S.T.; Ebell, M.H.; Vena, J.E.; Robb, S.W. Circadian disrupting exposures and breast cancer risk: A meta-analysis. *Int. Arch. Occup. Environ. Health* **2015**, *88*, 533–547. [[CrossRef](#)] [[PubMed](#)]
185. Sigurdardottir, L.G.; Valdimarsdottir, U.A.; Fall, K.; Rider, J.R.; Lockley, S.W.; Schernhammer, E.; Mucci, L.A. Circadian disruption, sleep loss, and prostate cancer risk: A systematic review of epidemiologic studies. *Cancer Epidemiol. Biomark. Prev.* **2012**, *21*, 1002–1011. [[CrossRef](#)] [[PubMed](#)]
186. Nakamura, E.; Kozaki, K.; Tsuda, H.; Suzuki, E.; Pimkhaokham, A.; Yamamoto, G.; Irie, T.; Tachikawa, T.; Amagasa, T.; Inazawa, J.; et al. Frequent silencing of a putative tumor suppressor gene melatonin receptor 1a (MTNR1A) in oral squamous-cell carcinoma. *Cancer Sci.* **2008**, *99*, 1390–1400. [[CrossRef](#)] [[PubMed](#)]
187. Jablonska, K.; Pula, B.; Zemla, A.; Owczarek, T.; Wojnar, A.; Rys, J.; Ambicka, A.; Podhorska-Okolow, M.; Ugorski, M.; Dziegiel, P. Expression of melatonin receptor mt1 in cells of human invasive ductal breast carcinoma. *J. Pineal Res.* **2013**, *54*, 334–345. [[CrossRef](#)] [[PubMed](#)]
188. Moroishi, T.; Hansen, C.G.; Guan, K.L. The emerging roles of yap and TAZ in cancer. *Nat. Rev. Cancer* **2015**, *15*, 73–79. [[CrossRef](#)] [[PubMed](#)]
189. Zhao, B.; Wei, X.; Li, W.; Udan, R.S.; Yang, Q.; Kim, J.; Xie, J.; Ikenoue, T.; Yu, J.; Li, L.; et al. Inactivation of yap oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. *Genes Dev.* **2007**, *21*, 2747–2761. [[CrossRef](#)] [[PubMed](#)]
190. Dong, J.; Feldmann, G.; Huang, J.; Wu, S.; Zhang, N.; Comerford, S.A.; Gayyed, M.F.; Anders, R.A.; Maitra, A.; Pan, D. Elucidation of a universal size-control mechanism in drosophila and mammals. *Cell* **2007**, *130*, 1120–1133. [[CrossRef](#)] [[PubMed](#)]
191. Hao, Y.; Chun, A.; Cheung, K.; Rashidi, B.; Yang, X. Tumor suppressor lats1 is a negative regulator of oncogene yap. *J. Biol. Chem.* **2008**, *283*, 5496–5509. [[CrossRef](#)] [[PubMed](#)]
192. Kanai, F.; Marignani, P.A.; Sarbassova, D.; Yagi, R.; Hall, R.A.; Donowitz, M.; Hisaminato, A.; Fujiwara, T.; Ito, Y.; Cantley, L.C.; et al. TAZ: A novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. *EMBO J.* **2000**, *19*, 6778–6791. [[CrossRef](#)] [[PubMed](#)]
193. Lei, Q.Y.; Zhang, H.; Zhao, B.; Zha, Z.Y.; Bai, F.; Pei, X.H.; Zhao, S.; Xiong, Y.; Guan, K.L. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the Hippo pathway. *Mol. Cell. Biol.* **2008**, *28*, 2426–2436. [[CrossRef](#)] [[PubMed](#)]
194. Vassilev, A.; Kaneko, K.J.; Shu, H.; Zhao, Y.; DePamphilis, M.L. TEAD/Tef Transcription factors utilize the activation domain of YAP65, a SRC/YES-associated protein localized in the cytoplasm. *Genes Dev.* **2001**, *15*, 1229–1241. [[CrossRef](#)] [[PubMed](#)]
195. Varelas, X.; Samavarchi-Tehrani, P.; Narimatsu, M.; Weiss, A.; Cockburn, K.; Larsen, B.G.; Rossant, J.; Wrana, J.L. The crumbs complex couples cell density sensing to Hippo-dependent control of the TGF- β -Smad pathway. *Dev. Cell* **2010**, *19*, 831–844. [[CrossRef](#)] [[PubMed](#)]
196. Zhao, B.; Li, L.; Tumaneng, K.; Wang, C.Y.; Guan, K.L. A coordinated phosphorylation by lats and CK1 regulates yap stability through SCF(β -Trcp). *Genes Dev.* **2010**, *24*, 72–85. [[CrossRef](#)] [[PubMed](#)]
197. Liu, C.Y.; Zha, Z.Y.; Zhou, X.; Zhang, H.; Huang, W.; Zhao, D.; Li, T.; Chan, S.W.; Lim, C.J.; Hong, W.; et al. The hippo tumor pathway promotes taz degradation by phosphorylating a phosphodegron and recruiting the SCF(β)-Trcp e3 ligase. *J. Biol. Chem.* **2010**, *285*, 37159–37169. [[CrossRef](#)] [[PubMed](#)]
198. Zanconato, F.; Battilana, G.; Cordenonsi, M.; Piccolo, S. YAP/TAZ as therapeutic targets in cancer. *Curr. Opin. Pharmacol.* **2016**, *29*, 26–33. [[CrossRef](#)] [[PubMed](#)]
199. Miller, E.; Yang, J.; DeRan, M.; Wu, C.; Su, A.I.; Bonamy, G.M.; Liu, J.; Peters, E.C.; Wu, X. Identification of serum-derived sphingosine-1-phosphate as a small molecule regulator of yap. *Chem. Biol.* **2012**, *19*, 955–962. [[CrossRef](#)] [[PubMed](#)]
200. Mo, J.S.; Yu, F.X.; Gong, R.; Brown, J.H.; Guan, K.L. Regulation of the Hippo-yap pathway by protease-activated receptors (pars). *Genes Dev.* **2012**, *26*, 2138–2143. [[CrossRef](#)] [[PubMed](#)]
201. Cai, H.; Xu, Y. The role of LPA and YAP signaling in long-term migration of human ovarian cancer cells. *Cell Commun. Signal.* **2013**, *11*, 31. [[CrossRef](#)] [[PubMed](#)]

202. Jeong, G.O.; Shin, S.H.; Seo, E.J.; Kwon, Y.W.; Heo, S.C.; Kim, K.H.; Yoon, M.S.; Suh, D.S.; Kim, J.H. Taz mediates lysophosphatidic acid-induced migration and proliferation of epithelial ovarian cancer cells. *Cell. Physiol. Biochem.* **2013**, *32*, 253–263. [[CrossRef](#)] [[PubMed](#)]
203. Yu, F.X.; Zhao, B.; Panupinthu, N.; Jewell, J.L.; Lian, I.; Wang, L.H.; Zhao, J.; Yuan, H.; Tumaneng, K.; Li, H.; et al. Regulation of the hippo-yap pathway by G-protein-coupled receptor signaling. *Cell* **2012**, *150*, 780–791. [[CrossRef](#)] [[PubMed](#)]
204. Kim, M.; Kim, M.; Lee, S.; Kuninaka, S.; Saya, H.; Lee, H.; Lee, S.; Lim, D.S. CAMP/PKA signalling reinforces the lats-yap pathway to fully suppress yap in response to actin cytoskeletal changes. *EMBO J.* **2013**, *32*, 1543–1555. [[CrossRef](#)] [[PubMed](#)]
205. Yu, F.X.; Zhang, Y.; Park, H.W.; Jewell, J.L.; Chen, Q.; Deng, Y.; Pan, D.; Taylor, S.S.; Lai, Z.C.; Guan, K.L. Protein kinase a activates the hippo pathway to modulate cell proliferation and differentiation. *Genes Dev.* **2013**, *27*, 1223–1232. [[CrossRef](#)] [[PubMed](#)]
206. Cho, H.H.; Shin, K.K.; Kim, Y.J.; Song, J.S.; Kim, J.M.; Bae, Y.C.; Kim, C.D.; Jung, J.S. NF- κ B activation stimulates osteogenic differentiation of mesenchymal stem cells derived from human adipose tissue by increasing taz expression. *J. Cell. Physiol.* **2010**, *223*, 168–177. [[PubMed](#)]
207. Brunn, G.J.; Hudson, C.C.; Sekulic, A.; Williams, J.M.; Hosoi, H.; Houghton, P.J.; Lawrence, J.C., Jr.; Abraham, R.T. Phosphorylation of the translational repressor PHAS-i by the mammalian target of rapamycin. *Science* **1997**, *277*, 99–101. [[CrossRef](#)] [[PubMed](#)]
208. Dennis, P.B.; Jaeschke, A.; Saitoh, M.; Fowler, B.; Kozma, S.C.; Thomas, G. Mammalian tor: A homeostatic atp sensor. *Science* **2001**, *294*, 1102–1105. [[CrossRef](#)] [[PubMed](#)]
209. Shamji, A.F.; Nghiem, P.; Schreiber, S.L. Integration of growth factor and nutrient signaling: Implications for cancer biology. *Mol. Cell* **2003**, *12*, 271–280. [[CrossRef](#)] [[PubMed](#)]
210. Inoki, K.; Li, Y.; Zhu, T.; Wu, J.; Guan, K.L. TSC2 is phosphorylated and inhibited by AKT and suppresses mTOR signalling. *Nat. Cell Biol.* **2002**, *4*, 648–657. [[CrossRef](#)] [[PubMed](#)]
211. Manning, B.D.; Tee, A.R.; Logsdon, M.N.; Blenis, J.; Cantley, L.C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberlin as a target of the phosphoinositide 3-kinase/AKT pathway. *Mol. Cell* **2002**, *10*, 151–162. [[CrossRef](#)]
212. Hao, F.; Xu, Q.; Zhao, Y.; Stevens, J.V.; Young, S.H.; Sinnett-Smith, J.; Rozengurt, E. Insulin receptor and gpcr crosstalk stimulates yap via PI3K and PKD in pancreatic cancer cells. *Mol. Cancer Res.* **2017**, *15*, 929–941. [[CrossRef](#)] [[PubMed](#)]
213. Wang, C.; Jeong, K.; Jiang, H.; Guo, W.; Gu, C.; Lu, Y.; Liang, J. YAP/TAZ Regulates the insulin signaling via IRS1/2 in endometrial cancer. *Am. J. Cancer Res.* **2016**, *6*, 996–1010. [[PubMed](#)]
214. Tumaneng, K.; Schlegelmilch, K.; Russell, R.C.; Yimlamai, D.; Basnet, H.; Mahadevan, N.; Fitamant, J.; Bardeesy, N.; Camargo, F.D.; Guan, K.L. Yap mediates crosstalk between the hippo and PI(3)K-TOR pathways by suppressing pten via MIR-29. *Nat. Cell Biol.* **2012**, *14*, 1322–1329. [[CrossRef](#)] [[PubMed](#)]
215. Fernandez, L.A.; Squatrito, M.; Northcott, P.; Awan, A.; Holland, E.C.; Taylor, M.D.; Nahle, Z.; Kenney, A.M. Oncogenic yap promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated AKT activation. *Oncogene* **2012**, *31*, 1923–1937. [[CrossRef](#)] [[PubMed](#)]
216. Lin, Z.; Zhou, P.; von Gise, A.; Gu, F.; Ma, Q.; Chen, J.; Guo, H.; van Gorp, P.R.; Wang, D.Z.; Pu, W.T. PI3KCB links hippo-yap and PI3K-AKT signaling pathways to promote cardiomyocyte proliferation and survival. *Circ. Res.* **2015**, *116*, 35–45. [[CrossRef](#)] [[PubMed](#)]
217. Wang, W.; Xiao, Z.D.; Li, X.; Aziz, K.E.; Gan, B.; Johnson, R.L.; Chen, J. AMPK modulates hippo pathway activity to regulate energy homeostasis. *Nat. Cell Biol.* **2015**, *17*, 490–499. [[CrossRef](#)] [[PubMed](#)]
218. Jung, J.H.; Sohn, E.J.; Shin, E.A.; Lee, D.; Kim, B.; Jung, D.B.; Kim, J.H.; Yun, M.; Lee, H.J.; Park, Y.K.; et al. Melatonin suppresses the expression of 45s preribosomal rna and upstream binding factor and enhances the antitumor activity of puromycin in MDA-MB-231 breast cancer cells. *Evid. Based Complement. Alternat. Med.* **2013**, *2013*, 879746. [[CrossRef](#)] [[PubMed](#)]
219. Liu, C.; Jia, Z.; Zhang, X.; Hou, J.; Wang, L.; Hao, S.; Ruan, X.; Yu, Z.; Zheng, Y. Involvement of melatonin in autophagy-mediated mouse hepatoma H22 cell survival. *Int. Immunopharmacol.* **2012**, *12*, 394–401. [[CrossRef](#)] [[PubMed](#)]
220. Kim, H.S.; Kim, T.J.; Yoo, Y.M. Melatonin combined with endoplasmic reticulum stress induces cell death via the PI3K/AKT/mTOR pathway in B16F10 melanoma cells. *PLoS ONE* **2014**, *9*, e92627. [[CrossRef](#)] [[PubMed](#)]

221. Porta, C.; Paglino, C.; Mosca, A. Targeting PI3K/AKT/mTOR signaling in cancer. *Front. Oncol.* **2014**, *4*, 64. [[CrossRef](#)] [[PubMed](#)]
222. Peschke, E.; Bahr, I.; Muhlbauer, E. Melatonin and pancreatic islets: Interrelationships between melatonin, insulin and glucagon. *Int. J. Mol. Sci.* **2013**, *14*, 6981–7015. [[CrossRef](#)] [[PubMed](#)]
223. Daulat, A.M.; Maurice, P.; Froment, C.; Guillaume, J.L.; Broussard, C.; Monsarrat, B.; Delagrangé, P.; Jockers, R. Purification and identification of G protein-coupled receptor protein complexes under native conditions. *Mol. Cell. Proteom.* **2007**, *6*, 835–844. [[CrossRef](#)] [[PubMed](#)]
224. Daulat, A.M.; Maurice, P.; Jockers, R. Recent methodological advances in the discovery of GPCR-associated protein complexes. *Trends Pharmacol. Sci.* **2009**, *30*, 72–78. [[CrossRef](#)] [[PubMed](#)]
225. Maurice, P.; Daulat, A.M.; Broussard, C.; Mozo, J.; Clary, G.; Hotellier, F.; Chafey, P.; Guillaume, J.L.; Ferry, G.; Boutin, J.A.; et al. A generic approach for the purification of signaling complexes that specifically interact with the carboxyl-terminal domain of G protein-coupled receptors. *Mol. Cell. Proteom.* **2008**, *7*, 1556–1569. [[CrossRef](#)] [[PubMed](#)]
226. Santinon, G.; Pocaterra, A.; Dupont, S. Control of YAP/TAZ activity by metabolic and nutrient-sensing pathways. *Trends Cell Biol.* **2016**, *26*, 289–299. [[CrossRef](#)] [[PubMed](#)]
227. Navarro-Alarcon, M.; Ruiz-Ojeda, F.J.; Blanca-Herrera, R.M.; MM, A.S.; Acuna-Castroviejo, D.; Fernandez-Vazquez, G.; Agil, A. Melatonin and metabolic regulation: A review. *Food Funct.* **2014**, *5*, 2806–2832. [[CrossRef](#)] [[PubMed](#)]
228. Cipolla-Neto, J.; Amaral, F.G.; Afeche, S.C.; Tan, D.X.; Reiter, R.J. Melatonin, energy metabolism, and obesity: A review. *J. Pineal Res.* **2014**, *56*, 371–381. [[CrossRef](#)] [[PubMed](#)]
229. Aragona, M.; Panciera, T.; Manfrin, A.; Giullitti, S.; Michielin, F.; Elvassore, N.; Dupont, S.; Piccolo, S. A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. *Cell* **2013**, *154*, 1047–1059. [[CrossRef](#)] [[PubMed](#)]
230. Driscoll, T.P.; Cosgrove, B.D.; Heo, S.J.; Shurden, Z.E.; Mauck, R.L. Cytoskeletal to nuclear strain transfer regulates yap signaling in mesenchymal stem cells. *Biophys. J.* **2015**, *108*, 2783–2793. [[CrossRef](#)] [[PubMed](#)]
231. Dupont, S.; Morsut, L.; Aragona, M.; Enzo, E.; Giullitti, S.; Cordenonsi, M.; Zanconato, F.; Le Digabel, J.; Forcato, M.; Bicciato, S.; et al. Role of YAP/TAZ in mechanotransduction. *Nature* **2011**, *474*, 179–183. [[CrossRef](#)] [[PubMed](#)]
232. Wada, K.; Itoga, K.; Okano, T.; Yonemura, S.; Sasaki, H. Hippo pathway regulation by cell morphology and stress fibers. *Development* **2011**, *138*, 3907–3914. [[CrossRef](#)] [[PubMed](#)]
233. Zhao, B.; Li, L.; Wang, L.; Wang, C.Y.; Yu, J.; Guan, K.L. Cell detachment activates the hippo pathway via cytoskeleton reorganization to induce anoikis. *Genes Dev.* **2012**, *26*, 54–68. [[CrossRef](#)] [[PubMed](#)]
234. Sun, Y.; Yong, K.M.; Villa-Diaz, L.G.; Zhang, X.; Chen, W.; Philson, R.; Weng, S.; Xu, H.; Krebsbach, P.H.; Fu, J. Hippo/YAP-mediated rigidity-dependent motor neuron differentiation of human pluripotent stem cells. *Nat. Mater.* **2014**, *13*, 599–604. [[CrossRef](#)] [[PubMed](#)]
235. Bertero, T.; Oldham, W.M.; Cottrill, K.A.; Pisano, S.; Vanderpool, R.R.; Yu, Q.; Zhao, J.; Tai, Y.; Tang, Y.; Zhang, Y.Y.; et al. Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension. *J. Clin. Investig.* **2016**, *126*, 3313–3335. [[CrossRef](#)] [[PubMed](#)]
236. Kim, N.G.; Gumbiner, B.M. Adhesion to fibronectin regulates hippo signaling via the FAK-SRC-PI3K pathway. *J. Cell Biol.* **2015**, *210*, 503–515. [[CrossRef](#)] [[PubMed](#)]
237. Benham-Pyle, B.W.; Pruitt, B.L.; Nelson, W.J. Cell adhesion. Mechanical strain induces e-cadherin-dependent yap1 and β -catenin activation to drive cell cycle entry. *Science* **2015**, *348*, 1024–1027. [[CrossRef](#)] [[PubMed](#)]
238. Bertero, T.; Cottrill, K.A.; Lu, Y.; Haeger, C.M.; Dieffenbach, P.; Annis, S.; Hale, A.; Bhat, B.; Kaimal, V.; Zhang, Y.Y.; et al. Matrix remodeling promotes pulmonary hypertension through feedback mechanoactivation of the YAP/TAZ-mir-130/301 circuit. *Cell Rep.* **2015**, *13*, 1016–1032. [[CrossRef](#)] [[PubMed](#)]
239. Calvo, F.; Ege, N.; Grande-Garcia, A.; Hooper, S.; Jenkins, R.P.; Chaudhry, S.I.; Harrington, K.; Williamson, P.; Moendarbary, E.; Charras, G.; et al. Mechanotransduction and yap-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. *Nat. Cell Biol.* **2013**, *15*, 637–646. [[CrossRef](#)] [[PubMed](#)]
240. Paszek, M.J.; DuFort, C.C.; Rossier, O.; Bainer, R.; Mouw, J.K.; Godula, K.; Hudak, J.E.; Lakins, J.N.; Wijekoon, A.C.; Cassereau, L.; et al. The cancer glycocalyx mechanically primes integrin-mediated growth and survival. *Nature* **2014**, *511*, 319–325. [[CrossRef](#)] [[PubMed](#)]

241. Rubashkin, M.G.; Cassereau, L.; Bainer, R.; DuFort, C.C.; Yui, Y.; Ou, G.; Paszek, M.J.; Davidson, M.W.; Chen, Y.Y.; Weaver, V.M. Force engages vinculin and promotes tumor progression by enhancing pi3k activation of phosphatidylinositol (3,4,5)-triphosphate. *Cancer Res.* **2014**, *74*, 4597–4611. [[CrossRef](#)] [[PubMed](#)]
242. Mouw, J.K.; Yui, Y.; Damiano, L.; Bainer, R.O.; Lakins, J.N.; Acerbi, I.; Ou, G.; Wijekoon, A.C.; Levental, K.R.; Gilbert, P.M.; et al. Tissue mechanics modulate microrna-dependent pten expression to regulate malignant progression. *Nat. Med.* **2014**, *20*, 360–367. [[CrossRef](#)] [[PubMed](#)]
243. Lin, C.H.; Pelissier, F.A.; Zhang, H.; Lakins, J.; Weaver, V.M.; Park, C.; LaBarge, M.A. Microenvironment rigidity modulates responses to the her2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors. *Mol. Biol. Cell* **2015**, *26*, 3946–3953. [[CrossRef](#)] [[PubMed](#)]
244. Bartucci, M.; Dattilo, R.; Moriconi, C.; Pagliuca, A.; Mottolese, M.; Federici, G.; Benedetto, A.D.; Todaro, M.; Stassi, G.; Sperati, F.; et al. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. *Oncogene* **2015**, *34*, 681–690. [[CrossRef](#)] [[PubMed](#)]
245. Cordenonsi, M.; Zanonato, F.; Azzolin, L.; Forcato, M.; Rosato, A.; Frasson, C.; Inui, M.; Montagner, M.; Parenti, A.R.; Poletti, A.; et al. The hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. *Cell* **2011**, *147*, 759–772. [[CrossRef](#)] [[PubMed](#)]
246. Lin, L.; Sabnis, A.J.; Chan, E.; Olivas, V.; Cade, L.; Pazarentzos, E.; Asthana, S.; Neel, D.; Yan, J.J.; Lu, X.; et al. The hippo effector yap promotes resistance to raf- and mek-targeted cancer therapies. *Nat. Genet.* **2015**, *47*, 250–256. [[CrossRef](#)] [[PubMed](#)]
247. Lee, J.E.; Park, H.S.; Lee, D.; Yoo, G.; Kim, T.; Jeon, H.; Yeo, M.K.; Lee, C.S.; Moon, J.Y.; Jung, S.S.; et al. Hippo pathway effector yap inhibition restores the sensitivity of egfr-tki in lung adenocarcinoma having primary or acquired egfr-tki resistance. *Biochem. Biophys. Res. Commun.* **2016**, *474*, 154–160. [[CrossRef](#)] [[PubMed](#)]
248. Cheng, H.; Zhang, Z.; Rodriguez-Barrueco, R.; Borczuk, A.; Liu, H.; Yu, J.; Silva, J.M.; Cheng, S.K.; Perez-Soler, R.; Halmos, B. Functional genomics screen identifies yap1 as a key determinant to enhance treatment sensitivity in lung cancer cells. *Oncotarget* **2016**, *7*, 28976–28988. [[CrossRef](#)] [[PubMed](#)]
249. Anton-Tay, F.; Ramirez, G.; Martinez, I.; Benitez-King, G. In vitro stimulation of protein kinase c by melatonin. *Neurochem. Res.* **1998**, *23*, 601–606. [[CrossRef](#)] [[PubMed](#)]
250. Benitez-King, G. PKC Activation by melatonin modulates vimentin intermediate filament organization in n1e-115 cells. *J. Pineal Res.* **2000**, *29*, 8–14. [[CrossRef](#)] [[PubMed](#)]
251. Benitez-King, G.; Hernandez, M.E.; Tovar, R.; Ramirez, G. Melatonin activates PKC- α but not pkc-epsilon in n1e-115 cells. *Neurochem. Int.* **2001**, *39*, 95–102. [[CrossRef](#)]
252. Koopman, M.G.; Koomen, G.C.; Krediet, R.T.; de Moor, E.A.; Hoek, F.J.; Arisz, L. Circadian rhythm of glomerular filtration rate in normal individuals. *Clin. Sci.* **1989**, *77*, 105–111. [[CrossRef](#)] [[PubMed](#)]
253. Richardson, B.A.; Studier, E.H.; Stallone, J.N.; Kennedy, C.M. Effects of melatonin on water metabolism and renal function in male syrian hamsters (*mesocricetus auratus*). *J. Pineal Res.* **1992**, *13*, 49–59. [[CrossRef](#)] [[PubMed](#)]
254. Lynch, C.D.; Sheetz, M.P. Cellular mechanotransduction: Filamin a strains to regulate motility. *Curr. Biol.* **2011**, *21*, R916–R918. [[CrossRef](#)] [[PubMed](#)]
255. Szymaniak, A.D.; Mahoney, J.E.; Cardoso, W.V.; Varelas, X. CRUMBS3-Mediated polarity directs airway epithelial cell fate through the hippo pathway effector yap. *Dev. Cell* **2015**, *34*, 283–296. [[CrossRef](#)] [[PubMed](#)]
256. Elbediwy, A.; Vincent-Mistiaen, Z.I.; Thompson, B.J. Yap and TAZ in epithelial stem cells: A sensor for cell polarity, mechanical forces and tissue damage. *Bioessays* **2016**, *38*, 644–653. [[CrossRef](#)] [[PubMed](#)]
257. Gumbiner, B.M.; Kim, N.G. The hippo-yap signaling pathway and contact inhibition of growth. *J. Cell Sci.* **2014**, *127*, 709–717. [[CrossRef](#)] [[PubMed](#)]
258. Genevet, A.; Wehr, M.C.; Brain, R.; Thompson, B.J.; Tapon, N. Kibra is a regulator of the salvador/warts/hippo signaling network. *Dev. Cell* **2010**, *18*, 300–308. [[CrossRef](#)] [[PubMed](#)]
259. Yu, J.; Zheng, Y.; Dong, J.; Klusza, S.; Deng, W.M.; Pan, D. Kibra functions as a tumor suppressor protein that regulates hippo signaling in conjunction with merlin and expanded. *Dev. Cell* **2010**, *18*, 288–299. [[CrossRef](#)] [[PubMed](#)]
260. Zhao, B.; Li, L.; Lu, Q.; Wang, L.H.; Liu, C.Y.; Lei, Q.; Guan, K.L. Angiomotin is a novel hippo pathway component that inhibits yap oncoprotein. *Genes Dev.* **2011**, *25*, 51–63. [[CrossRef](#)] [[PubMed](#)]
261. Chen, C.L.; Gajewski, K.M.; Hamaratoglu, F.; Bossuyt, W.; Sansores-Garcia, L.; Tao, C.; Halder, G. The apical-basal cell polarity determinant crumbs regulates hippo signaling in drosophila. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 15810–15815. [[CrossRef](#)] [[PubMed](#)]

262. Gurvich, N.; Perna, F.; Farina, A.; Voza, F.; Menendez, S.; Hurwitz, J.; Nimer, S.D. L3MBTL1 Polycomb protein, a candidate tumor suppressor in del(20q12) myeloid disorders, is essential for genome stability. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 22552–22557. [[CrossRef](#)] [[PubMed](#)]
263. Ling, C.; Zheng, Y.; Yin, F.; Yu, J.; Huang, J.; Hong, Y.; Wu, S.; Pan, D. The apical transmembrane protein crumbs functions as a tumor suppressor that regulates hippo signaling by binding to expanded. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 10532–10537. [[CrossRef](#)] [[PubMed](#)]
264. Robinson, B.S.; Huang, J.; Hong, Y.; Moberg, K.H. Crumbs regulates salvador/warts/hippo signaling in drosophila via the ferm-domain protein expanded. *Curr. Biol.* **2010**, *20*, 582–590. [[CrossRef](#)] [[PubMed](#)]
265. Elbediwy, A.; Vincent-Mistiaen, Z.I.; Spencer-Dene, B.; Stone, R.K.; Boeing, S.; Wculek, S.K.; Cordero, J.; Tan, E.H.; Ridgway, R.; Brunton, V.G.; et al. Integrin signalling regulates yap and TAZ to control skin homeostasis. *Development* **2016**, *143*, 1674–1687. [[CrossRef](#)] [[PubMed](#)]
266. Das Thakur, M.; Feng, Y.; Jagannathan, R.; Seppa, M.J.; Skeath, J.B.; Longmore, G.D. Ajuba lim proteins are negative regulators of the hippo signaling pathway. *Curr. Biol.* **2010**, *20*, 657–662. [[CrossRef](#)] [[PubMed](#)]
267. Nguyen, H.B.; Babcock, J.T.; Wells, C.D.; Quilliam, L.A. Lkb1 tumor suppressor regulates amp kinase/mTOR-independent cell growth and proliferation via the phosphorylation of yap. *Oncogene* **2013**, *32*, 4100–4109. [[CrossRef](#)] [[PubMed](#)]
268. Remue, E.; Meerschaert, K.; Oka, T.; Boucherie, C.; Vandekerckhove, J.; Sudol, M.; Gettemans, J. TAZ interacts with zonula occludens-1 and -2 proteins in a pdz-1 dependent manner. *FEBS Lett.* **2010**, *584*, 4175–4180. [[CrossRef](#)] [[PubMed](#)]
269. Oka, T.; Remue, E.; Meerschaert, K.; Vanloo, B.; Boucherie, C.; Gfeller, D.; Bader, G.D.; Sidhu, S.S.; Vandekerckhove, J.; Gettemans, J.; et al. Functional complexes between yap2 and zo-2 are pdz domain-dependent, and regulate yap2 nuclear localization and signalling. *Biochem. J.* **2010**, *432*, 461–472. [[CrossRef](#)] [[PubMed](#)]
270. Kim, N.G.; Koh, E.; Chen, X.; Gumbiner, B.M. E-cadherin mediates contact inhibition of proliferation through hippo signaling-pathway components. *Proc. Natl. Acad. Sci. USA* **2011**, *108*, 11930–11935. [[CrossRef](#)] [[PubMed](#)]
271. Schlegelmilch, K.; Mohseni, M.; Kirak, O.; Pruszk, J.; Rodriguez, J.R.; Zhou, D.; Kreger, B.T.; Vasioukhin, V.; Avruch, J.; Brummelkamp, T.R.; et al. Yap1 acts downstream of α -catenin to control epidermal proliferation. *Cell* **2011**, *144*, 782–795. [[CrossRef](#)] [[PubMed](#)]
272. Liu, X.; Yang, N.; Figel, S.A.; Wilson, K.E.; Morrison, C.D.; Gelman, I.H.; Zhang, J. Ptpn14 interacts with and negatively regulates the oncogenic function of yap. *Oncogene* **2013**, *32*, 1266–1273. [[CrossRef](#)] [[PubMed](#)]
273. Anastasiadis, P.Z.; Moon, S.Y.; Thoreson, M.A.; Mariner, D.J.; Crawford, H.C.; Zheng, Y.; Reynolds, A.B. Inhibition of rhoa by p120 catenin. *Nat. Cell Biol.* **2000**, *2*, 637–644. [[PubMed](#)]
274. Grosheva, I.; Shtutman, M.; Elbaum, M.; Bershadsky, A.D. P120 catenin affects cell motility via modulation of activity of rho-family gtpases: A link between cell-cell contact formation and regulation of cell locomotion. *J. Cell Sci.* **2001**, *114*, 695–707. [[PubMed](#)]
275. Noren, N.K.; Liu, B.P.; Burridge, K.; Kreft, B. P120 catenin regulates the actin cytoskeleton via rho family gtpases. *J. Cell Biol.* **2000**, *150*, 567–580. [[CrossRef](#)] [[PubMed](#)]
276. Zhu, Y.T.; Chen, H.C.; Chen, S.Y.; Tseng, S.C. Nuclear p120 catenin unlocks mitotic block of contact-inhibited human corneal endothelial monolayers without disrupting adherent junctions. *J. Cell Sci.* **2012**, *125*, 3636–3648. [[CrossRef](#)] [[PubMed](#)]
277. Ireton, R.C.; Davis, M.A.; van Hengel, J.; Mariner, D.J.; Barnes, K.; Thoreson, M.A.; Anastasiadis, P.Z.; Matrisian, L.; Bundy, L.M.; Sealy, L.; et al. A novel role for p120 catenin in e-cadherin function. *J. Cell Biol.* **2002**, *159*, 465–476. [[CrossRef](#)] [[PubMed](#)]
278. Davis, M.A.; Ireton, R.C.; Reynolds, A.B. A core function for p120-catenin in cadherin turnover. *J. Cell Biol.* **2003**, *163*, 525–534. [[CrossRef](#)] [[PubMed](#)]
279. Xiao, K.; Allison, D.F.; Buckley, K.M.; Kottke, M.D.; Vincent, P.A.; Faundez, V.; Kowalczyk, A.P. Cellular levels of p120 catenin function as a set point for cadherin expression levels in microvascular endothelial cells. *J. Cell Biol.* **2003**, *163*, 535–545. [[CrossRef](#)] [[PubMed](#)]
280. Yang, C.C.; Graves, H.K.; Moya, I.M.; Tao, C.; Hamaratoglu, F.; Gladden, A.B.; Halder, G. Differential regulation of the hippo pathway by adherens junctions and apical-basal cell polarity modules. *Proc. Natl. Acad. Sci. USA* **2015**, *112*, 1785–1790. [[CrossRef](#)] [[PubMed](#)]
281. Bar-Sagi, D.; Hall, A. Ras and rho gtpases: A family reunion. *Cell* **2000**, *103*, 227–238. [[CrossRef](#)]

282. Parri, M.; Chiarugi, P. Rac and rho gtpases in cancer cell motility control. *Cell Commun. Signal.* **2010**, *8*, 23. [[CrossRef](#)] [[PubMed](#)]
283. Arthur, W.T.; Quilliam, L.A.; Cooper, J.A. Rap1 promotes cell spreading by localizing rac guanine nucleotide exchange factors. *J. Cell Biol.* **2004**, *167*, 111–122. [[CrossRef](#)] [[PubMed](#)]
284. Stiffler, M.A.; Chen, J.R.; Grantcharova, V.P.; Lei, Y.; Fuchs, D.; Allen, J.E.; Zaslavskaya, L.A.; MacBeath, G. Pdz domain binding selectivity is optimized across the mouse proteome. *Science* **2007**, *317*, 364–369. [[CrossRef](#)] [[PubMed](#)]
285. Guillaume, J.L.; Daulat, A.M.; Maurice, P.; Levoe, A.; Migaud, M.; Brydon, L.; Malpoux, B.; Borg-Capra, C.; Jockers, R. The pdz protein mupp1 promotes gi coupling and signaling of the mt1 melatonin receptor. *J. Biol. Chem.* **2008**, *283*, 16762–16771. [[CrossRef](#)] [[PubMed](#)]
286. Hamazaki, Y.; Itoh, M.; Sasaki, H.; Furuse, M.; Tsukita, S. Multi-pdz domain protein 1 (mupp1) is concentrated at tight junctions through its possible interaction with claudin-1 and junctional adhesion molecule. *J. Biol. Chem.* **2002**, *277*, 455–461. [[CrossRef](#)] [[PubMed](#)]
287. Meyer, T.N.; Schwesinger, C.; Denker, B.M. Zonula occludens-1 is a scaffolding protein for signaling molecules. $\alpha(12)$ directly binds to the src homology 3 domain and regulates paracellular permeability in epithelial cells. *J. Biol. Chem.* **2002**, *277*, 24855–24858. [[CrossRef](#)] [[PubMed](#)]
288. Sabath, E.; Negoro, H.; Beaudry, S.; Paniagua, M.; Angelow, S.; Shah, J.; Grammatikakis, N.; Yu, A.S.; Denker, B.M. $\alpha(12)$ regulates protein interactions within the mdck cell tight junction and inhibits tight-junction assembly. *J. Cell Sci.* **2008**, *121*, 814–824. [[CrossRef](#)] [[PubMed](#)]
289. Clattenburg, L.; Wigerius, M.; Qi, J.; Rainey, J.K.; Rourke, J.L.; Muruganandan, S.; Sinal, C.J.; Fawcett, J.P. Nos1ap functionally associates with yap to regulate hippo signaling. *Mol. Cell. Biol.* **2015**, *35*, 2265–2277. [[CrossRef](#)] [[PubMed](#)]
290. Alzahrani, F.; Clattenburg, L.; Muruganandan, S.; Bullock, M.; MacIsaac, K.; Wigerius, M.; Williams, B.A.; Graham, M.E.; Rigby, M.H.; Trites, J.R.; et al. The hippo component yap localizes in the nucleus of human papilloma virus positive oropharyngeal squamous cell carcinoma. *J. Otolaryngol. Head Neck Surg.* **2017**, *46*, 15. [[CrossRef](#)] [[PubMed](#)]
291. Mohseni, M.; Sun, J.; Lau, A.; Curtis, S.; Goldsmith, J.; Fox, V.L.; Wei, C.; Frazier, M.; Samson, O.; Wong, K.K.; et al. A genetic screen identifies an lkb1-mark signalling axis controlling the hippo-yap pathway. *Nat. Cell Biol.* **2014**, *16*, 108–117. [[CrossRef](#)] [[PubMed](#)]
292. Treeck, O.; Haldar, C.; Ortmann, O. Antiestrogens modulate mt1 melatonin receptor expression in breast and ovarian cancer cell lines. *Oncol. Rep.* **2006**, *15*, 231–235. [[CrossRef](#)] [[PubMed](#)]
293. Powzaniuk, M.; McElwee-Witmer, S.; Vogel, R.L.; Hayami, T.; Rutledge, S.J.; Chen, F.; Harada, S.; Schmidt, A.; Rodan, G.A.; Freedman, L.P.; et al. The lats2/kpm tumor suppressor is a negative regulator of the androgen receptor. *Mol. Endocrinol.* **2004**, *18*, 2011–2023. [[CrossRef](#)] [[PubMed](#)]
294. Lit, L.C.; Scott, S.; Zhang, H.; Stebbing, J.; Photiou, A.; Giamas, G. Lats2 is a modulator of estrogen receptor α . *Anticancer Res.* **2013**, *33*, 53–63. [[PubMed](#)]
295. Britschgi, A.; Duss, S.; Kim, S.; Couto, J.P.; Brinkhaus, H.; Koren, S.; De Silva, D.; Mertz, K.D.; Kaup, D.; Varga, Z.; et al. The hippo kinases lats1 and 2 control human breast cell fate via crosstalk with ER α . *Nature* **2017**, *541*, 541–545. [[CrossRef](#)] [[PubMed](#)]
296. Ma, B.; Chen, Y.; Chen, L.; Cheng, H.; Mu, C.; Li, J.; Gao, R.; Zhou, C.; Cao, L.; Liu, J.; et al. Hypoxia regulates hippo signalling through the sia2 ubiquitin e3 ligase. *Nat. Cell Biol.* **2015**, *17*, 95–103. [[CrossRef](#)] [[PubMed](#)]
297. Zanonato, F.; Piccolo, S. Eradicating tumor drug resistance at its yap-biomechanical roots. *EMBO J.* **2016**, *35*, 459–461. [[CrossRef](#)] [[PubMed](#)]

